Stent with multiple bridge length pattern

A stent with a polynomial function-based pattern and retrograde blood flow system addresses the flexibility and conformity issues of current stents, enhancing the effectiveness of carotid angioplasty and stenting by reducing emboli and improving blood flow dynamics.

JP2024545417APending Publication Date: 2024-12-06SILK ROAD MEDICAL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532424
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-30
Filing Date
2022-11-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current stents used in carotid angioplasty and stenting have low flexibility, fail to conform well to the carotid artery anatomy, and can cause vessel bending, leading to potential embolic particle release and reduced effectiveness in treating carotid artery disease.

Method used

A stent design with a tubular body featuring varying bridge lengths and configurations, including a polynomial function-based pattern, to enhance flexibility and conformability, along with a retrograde blood flow system to limit emboli release and improve blood flow dynamics during carotid interventions.

Benefits of technology

The stent design improves conformity to the carotid artery anatomy, reducing the risk of emboli and enhancing the effectiveness of carotid angioplasty and stenting procedures by promoting retrograde blood flow, thereby minimizing neurological risks and improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545417000001_ABST
    Figure 2024545417000001_ABST
Patent Text Reader

Abstract

In the present disclosure, various embodiments of stents are proposed having various pattern variations defined by polynomial functions, such as fourth order polynomials. For example, the pattern variations include varying lengths of the bridges and / or struts forming the stent along the length of the stent. The pattern variations can help achieve desirable flexibility and conformance to varying vasculature along the length of the stent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CROSS-REFERENCE TO RELATED APPLICATIONS] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 63 / 284,227, filed November 30, 2021, and entitled “STENT WITH MULTIPLE BRIDGE LENGTH PATTERN,” the entire contents of which are incorporated herein by reference. [Background technology]

[0002] Carotid artery disease usually results from the deposition of plaque P that narrows the junction between the common carotid artery (CCA) and the internal carotid artery (ICA), the artery that supplies blood flow to the brain (Figure 5). These deposits increase the risk of embolic particles being generated and entering the cerebral vasculature, causing neurological consequences such as transient ischemic attacks (TIAs), ischemic strokes, or death. Furthermore, if such narrowing becomes severe, it can impede blood flow to the brain, with serious, even fatal, consequences.

[0003] Two main therapies are used to treat carotid artery disease. The first is carotid endarterectomy (CEA), which is an open procedure that occludes the common, internal and external carotid arteries, opens the carotid artery at the diseased site (usually the carotid bifurcation where the common carotid artery (CCA) branches into the internal carotid artery (ICA) and external carotid artery (ECA)), ablates and removes the plaque P, and closes the carotid artery. The second procedure relies on carotid angioplasty and / or carotid artery stenting (CAS), which is usually performed at or across the bifurcation of the common carotid artery (CCA) to the internal carotid artery (ICA), or entirely within the internal carotid artery. A balloon catheter and / or a self-expanding stent can be introduced and deployed into the targeted common carotid artery (CCA). At least some currently available stents are less flexible, causing vessel bending and may not conform well to the anatomy.

[0004] For these reasons, it would be desirable to provide improved methods, devices, and systems for performing carotid angioplasty (e.g., via transcarotid access) and implantation of a stent in the carotid vasculature to improve the effectiveness and efficiency of carotid angioplasty and / or stent placement. At least some of these objectives will be achieved by the inventions described below. Summary of the Invention

[0005] Aspects of the present invention relate to stents according to various embodiments capable of treating atherosclerosis in arterial vessels, such as carotid vessels. In one aspect, a stent may comprise an elongate tubular body configured to be capable of forming a contracted (folded) configuration and an expanded configuration. The tubular body may extend along a longitudinal axis, the tubular body may comprise a plurality of strut rings extending circumferentially about the longitudinal axis and a plurality of bridges each configured to connect two adjacent strut rings. The plurality of bridges may include a first group of bridges each having a first length and comprising at least two bridges capable of connecting a first pair of strut rings of the plurality of strut rings, a second group of bridges each having a second length and comprising at least two bridges capable of connecting a second pair of strut rings of the plurality of strut rings, and a third group of bridges each having a third length and comprising at least two bridges capable of connecting a third pair of strut rings of the plurality of strut rings. The second length may be longer than the first length and the third length may be longer than the second length. The first bridge group may be disposed at a first location along the longitudinal axis, the second bridge group may be disposed at a second location along the longitudinal axis, and the third bridge group may be disposed at a third location along the longitudinal axis. The first length at the first location, the second length at the second location, and the third length at the third location may be defined by a polynomial function based on at least the length of the stent.

[0006] In some embodiments, one or more of the following features may be optionally included in any workable combination. For example, the tubular body may include a proximal section having at least one circumferential row of open cells. The proximal section may be free of closed cells. The tubular body may include a middle section having at least one circumferential row of closed cells. The middle section may be free of open cells. The tubular body may include a distal section having at least one circumferential row of open cells. The distal section may be free of closed cells. The first length, the second length, and the third length of the bridges may increase progressively from the proximal section to the middle section. Each strut ring in the plurality of strut rings may include struts having the same length as one another. Each strut ring in the plurality of strut rings may include struts having different lengths as one another, and the length of the struts may increase along the stent. The bridges may increase in length from a midline of the stent. Each bridge in the plurality of bridges may have a non-linear shape. The first location may be adjacent a proximal end of the stent and the third location may be adjacent a distal end of the stent.

[0007] In another related aspect of the invention, a method of operating a stent for treating atherosclerosis in an arterial vasculature may include contracting the stent to a contracted (folded) configuration, for example for inserting the stent into the arterial vasculature. The method of operating the stent may include expanding the stent to an expanded configuration, for example for at least partially conforming the stent to the arterial vasculature. The stent may include an elongate tubular body configured to be capable of forming a contracted configuration and an expanded configuration. The tubular body may extend along a longitudinal axis and may include a plurality of strut rings extending circumferentially around the longitudinal axis and a plurality of bridges each configured to connect two adjacent strut rings. The plurality of bridges may include a first group of bridges having at least two bridges each having a first length and capable of connecting a first pair of strut rings of the plurality of strut rings, a second group of bridges having a second length and capable of connecting a second pair of strut rings of the plurality of strut rings, and a third group of bridges having at least two bridges each having a third length and capable of connecting a third pair of strut rings of the plurality of strut rings. The second length may be longer than the first length, and the third length may be longer than the second length. The first group of bridges may be disposed at a first location along the longitudinal axis, the second group of bridges may be disposed at a second location along the longitudinal axis, and the third group of bridges may be disposed at a third location along the longitudinal axis. The first length at the first location, the second length at the second location, and the third length at the third location may be defined by a polynomial function based on at least the length of the stent.

[0008] In some embodiments, one or more of the following features may be optionally included in any workable combination. For example, the tubular body may include a proximal section having at least one circumferential row of open cells. The proximal section may be free of closed cells. The tubular body may include a middle section having at least one circumferential row of closed cells. The middle section may be free of open cells. The tubular body may include a distal section having at least one circumferential row of open cells. The distal section may be free of closed cells. The first length, the second length, and the third length of the bridges may increase progressively from the proximal section to the middle section. Each strut ring in the plurality of strut rings may include struts having the same length as one another. Each strut ring in the plurality of strut rings may include struts having different lengths as one another, and the length of the struts may increase along the stent. The bridges may increase in length from a midline of the stent. Each bridge in the plurality of bridges may have a non-linear shape. The first location may be adjacent a proximal end of the stent and the third location may be adjacent a distal end of the stent.

[0009] In some embodiments, the methods, devices, and systems disclosed herein establish and promote retrograde or reverse blood flow in the area of ​​the carotid bifurcation to limit or prevent the release of emboli into the cerebral vasculature, particularly the internal carotid artery. Also disclosed herein are methods, devices, and systems for interventional procedures, such as stenting and angioplasty, atherectomy, etc., performed via a transcarotid approach to the common carotid artery using open surgical techniques or percutaneous techniques, such as modified Seldinger technique or micropuncture techniques. Additionally, various methods, devices, and systems related to balloon catheters configured to perform carotid angioplasty and / or assist in the placement of carotid stents are disclosed herein.

[0010] In some embodiments, access to the common carotid artery (FIG. 5) is established by placing a sheath or other tubular access cannula within the lumen of the artery, typically with the distal end of the sheath positioned proximal to the junction or bifurcation B of the common carotid artery to the internal and external carotid arteries. The sheath may have an occlusion member, such as, for example, a conformal occlusion balloon, at its distal end. A catheter or guidewire with an occlusion member, such as an occlusion balloon, may be placed through the access sheath into the proximal external carotid artery (ECA) to prevent entry of emboli, although it is not usually necessary to occlude the external carotid artery. A second return sheath is placed into the venous system, such as the internal jugular vein (IJV) or femoral vein (FV). The arterial access sheath and the venous return sheath are connected together to form an external arterial-venous shunt.

[0011] Retrograde blood flow can be established and adjusted to suit the patient's needs. Blood flow through the common carotid artery is occluded by an external vascular loop or tape, a vascular clamp, an internal occlusion member such as an occlusion balloon, or other type of occlusion means. When blood flow through the common carotid artery is blocked, the natural pressure gradient between the internal carotid artery and the venous system causes blood to flow in the retrograde direction from the cerebral vessels, through the internal carotid artery, and through the shunt into the venous system.

[0012] Alternatively, the venous sheath may be omitted and the arterial sheath may be connected to an external collection reservoir or container, in which retrograde blood flow is collected. If desired, the collected blood may be filtered and returned to the patient during or at the end of the procedure. The pressure in the container may be released to atmospheric pressure, allowing a pressure gradient to drive blood back from the cerebral vasculature to the container, or the pressure in the container may be negative.

[0013] If necessary, to achieve or enhance retrograde blood flow from the internal carotid artery, blood flow from the external carotid artery can be blocked, usually by placing an occlusion balloon or other occlusion element in the external carotid artery just above (i.e., distal to) the bifurcation in the internal carotid artery.

[0014] Although the procedures and procedures described below are directed specifically to carotid angioplasty and / or carotid stenting, it will be appreciated that the carotid access methods described herein are also useful for atherectomy and other interventional procedures that may be performed in the carotid system, particularly at locations near the bifurcation of the internal and external carotid arteries. Additionally, it will be appreciated that some of these access, vascular occlusion, embolization and protection methods may also be applicable to other vascular interventional procedures, such as the treatment of acute stroke.

[0015] The disclosure herein includes several specific aspects for improving the performance of carotid access and treatment procedures. At least most of these individual aspects and improvements may be implemented individually or in combination with one or more other improvements to facilitate and enhance the performance of a particular intervention in the carotid system. The disclosure herein also includes various embodiments of stents for improving the stenting of various blood vessels.

[0016] Details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will be apparent from the following description and drawings, and from the claims. [Brief description of the drawings]

[0017] [Figure 1A] 1 is a schematic diagram of a retrograde blood flow system including a flow control assembly with an arterial access device accessing the common carotid artery via a transcarotid approach and a venous return device in communication with the internal jugular vein. [Figure 1B] FIG. 1 is a schematic diagram of a retrograde blood flow system with an arterial access device accessing the common carotid artery via a transcarotid approach and a venous return device communicating with the femoral vein. [Figure 1C] FIG. 1 is a schematic diagram of a retrograde blood flow system with an arterial access device accessing the common carotid artery via a transfemoral approach and a venous return device in communication with the femoral vein. [Figure 1D]FIG. 1 is a schematic diagram of a retrograde blood flow system with retrograde blood flow collected in an external reservoir. [Figure 1E] FIG. 1 is a schematic diagram of an alternative retrograde blood flow system, with an arterial access device accessing the common carotid artery via a transcarotid approach and a venous return device communicating with the femoral vein. [Figure 2A] FIG. 1 is an enlarged view of the carotid artery after it has been occluded by an occlusion element on a sheath and connected to a retrograde shunt, and an interventional device, such as a stent delivery system or other working catheter, has been introduced into the carotid artery via an arterial access device. [Figure 2B] 1 shows an alternative system in which the carotid artery is occluded with a separate external occlusion device and connected to a retrograde shunt, and an interventional device, such as a stent delivery system or other working catheter, is introduced into the carotid artery via the arterial access device. [Figure 2C] 1 shows an alternative system in which the carotid artery is connected to a retrograde shunt, an interventional device such as a stent delivery system or other working catheter is introduced into the carotid artery via an arterial access device, and the carotid artery is occluded using a separate occlusion device. [Figure 2D] 1 shows an alternative system in which the carotid artery is occluded and connected to a retrograde shunt via an arterial access device, and an interventional device, such as a stent delivery system, is introduced into the carotid artery via a separate arterial introducer device. [Diagram 3] 1 shows a conventional Criado flow shunt system. [Figure 4] A diagram of normal cerebral circulation including the Circle of Willis is shown. [Diagram 5] The vasculature of a patient's neck is shown, including the common carotid artery (CCA), internal carotid artery (ICA), external carotid artery (ECA), and internal jugular vein (IJV). [Figure 6A] 1 illustrates an arterial access device useful in the methods and systems of the present disclosure. [Figure 6B] 1 illustrates an arterial access device configuration with a narrowed distal end. [Figure 7A] A tube that can be used with the sheath of FIG. 6A is shown. [Figure 7B]A tube that can be used with the sheath of FIG. 6A is shown. [Figure 7C] 1 shows an embodiment of a sheath stopper. [Figure 7D] 7D shows the sheath stopper of FIG. 7C placed on a sheath. [Figure 7E] 1 shows the malleable sheath stopper in use. [Figure 7F] 1 shows the malleable sheath stopper in use. [Figure 7G] 1 illustrates an embodiment of a sheath with a flexible distal section and a sheath stopper in a use configuration. [Figure 8A] 13 illustrates a further arterial access device configuration with an expandable occlusion element. [Figure 8B] 1 illustrates a further arterial access device configuration with an expandable occlusion element and a reduced diameter distal end. [Figure 9A] 1 illustrates a further embodiment of an arterial access device. [Figure 9B] 1 illustrates a further embodiment of an arterial access device. [Figure 9C] 1 illustrates an embodiment of a valve on an arterial access device. [Figure 9D] 1 illustrates an embodiment of a valve on an arterial access device. [Figure 10A] 1 illustrates an embodiment of a venous return device useful in the methods and systems of the present disclosure. [Figure 10B] 1 illustrates an embodiment of a venous return device useful in the methods and systems of the present disclosure. [Figure 10C] 1 illustrates an embodiment of a venous return device useful in the methods and systems of the present disclosure. [Figure 10D] 1 illustrates an embodiment of a venous return device useful in the methods and systems of the present disclosure. [Figure 11] 2 illustrates the system of FIG. 1 including a flow control assembly. [Figure 12A] 1 illustrates an embodiment of a variable flow resistance component useful in the methods and systems of the present disclosure. [Figure 12B]1 illustrates an embodiment of a variable flow resistance component useful in the methods and systems of the present disclosure. [Figure 13A] 1 illustrates an embodiment of a flow control assembly in a single housing. [Figure 13B] 1 illustrates an embodiment of a flow control assembly in a single housing. [Figure 13C] 1 illustrates an embodiment of a flow control assembly in a single housing. [Figure 14A] 1 illustrates an exemplary blood flow pathway during a procedure in which carotid angioplasty is performed in accordance with the principles of the present disclosure and a stent is implanted at the carotid bifurcation. [Figure 14B] 1 illustrates an exemplary blood flow pathway during a procedure in which carotid angioplasty is performed in accordance with the principles of the present disclosure and a stent is implanted at the carotid bifurcation. [Figure 14C] 1 illustrates an embodiment of a balloon catheter for performing carotid angioplasty. [Figure 14D] 1 illustrates an embodiment of a balloon catheter for performing carotid angioplasty. [Figure 14E] 1 shows the deployment of a stent at the carotid bifurcation. [Figure 14F] 1 shows the deployment of a stent at the carotid bifurcation. [Figure 14G] 1 shows the deployment of a stent at the carotid bifurcation. [Figure 14H] 1 illustrates an embodiment of a balloon catheter for performing post-deployment expansion of a stent. [Figure 15A] 1 shows examples of the configuration of a kit and a package. [Figure 15B] 1 shows examples of the configuration of a kit and a package. [Figure 15C] 1 shows examples of the configuration of a kit and a package. [Figure 15D] 1 shows examples of the configuration of a kit and a package. [Figure 16A] 1 shows a side view of a stent according to one embodiment configured for use in a carotid artery, the stent including a first pattern change. [Figure 16B]1 shows a side view of a stent according to one embodiment configured for use in a carotid artery, the stent including a first pattern change. [Figure 16C] 16C is a graph showing the variation in bridge length along the stent of FIGS. 16A-16B, where the variation in bridge length is determined by a polynomial function. [Figure 17A] 1 illustrates a side view of a stent according to one embodiment configured for use in a carotid artery, the stent including a second pattern change. [Figure 17B] 1 illustrates a side view of a stent according to one embodiment configured for use in a carotid artery, the stent including a second pattern change. [Figure 17C] 17C is a graph showing the variation in bridge length along the stent of FIGS. 17A-17B, where the variation in bridge length is determined by a polynomial function. [Figure 18A] 1 illustrates a side view of a stent according to one embodiment configured for use in a carotid artery, the stent including a third pattern variation. [Figure 18B] 1 illustrates a side view of a stent according to one embodiment configured for use in a carotid artery, the stent including a third pattern variation. [Figure 18C] 18C is a graph showing the variation in bridge length along the stent of FIGS. 18A-18B, where the variation in bridge length is determined by a polynomial function. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present disclosure relates generally to medical methods and medical devices. More specifically, the present disclosure relates to methods and systems for accessing the carotid vasculature and establishing retrograde blood flow, performing carotid angioplasty, carotid stenting, and other procedures. For example, various embodiments of stents are described herein having various pattern variations defined by polynomial functions, such as fourth order polynomials.

[0019] FIG. 1A illustrates a retrograde blood flow system 100 according to a first embodiment. The retrograde blood flow system 100 is configured to establish and promote retrograde or reverse blood circulation in the region of the carotid artery bifurcation to limit or prevent the release of emboli into the cerebral vasculature, particularly the internal carotid artery. The retrograde blood flow system 100 interacts with the carotid artery to provide retrograde blood flow from the carotid artery to a venous return site, such as the internal jugular vein (or in alternative embodiments, another return site, such as another large vein or an external vessel). The retrograde blood flow system 100 includes an arterial access device 110, a venous return device 115, and a shunt 120 that provides a passage for reverse flow (retrograde blood flow) from the arterial access device 110 to the venous return device 115. A flow control assembly 125 interacts with the shunt 120. The flow control assembly 125 is configured to regulate and / or monitor the reverse flow from the common carotid artery to the internal jugular vein, as described in more detail below. The flow control assembly 125 interacts with the flow path via the shunt 120, either external to the flow path, internal to the flow path, or both. As described in more detail below, the arterial access device 110 is inserted at least partially into the common carotid artery (CCA), and the venous return device 115 is inserted at least partially into a venous return site, such as the internal jugular vein (IJV). The arterial access device 110 and the venous return device 115 couple to the shunt 120 at connection locations 127a, 127b. When blood flow through the common carotid artery is blocked, a natural pressure gradient between the internal carotid artery and the venous system causes blood to flow in a retrograde or retrograde RG direction (FIG. 2A) from the cerebral vasculature through the internal carotid artery and the shunt 120 into the venous system. The flow control assembly 125 regulates, augments, assists, monitors, and / or otherwise modulates the retrograde blood flow.

[0020] In the embodiment of FIG. 1A, the arterial access device 110 accesses the common carotid artery (CCA) via a transcarotid approach. Transcarotid access provides a short, non-tortuous path from the vascular access point to the target treatment site, which reduces the time and difficulty of the procedure compared to, for example, a transfemoral approach. In one embodiment, the arterial distance (measured through the artery) from the arteriotomy to the target treatment site is typically 15 cm or less. In one embodiment, the arterial distance may be 5-10 cm. Additionally, this access route reduces the risk of embolic generation when passing through diseased, angulated, or tortuous aortic arch or common carotid anatomy. At least a portion of the venous return device 115 is placed in the internal jugular vein (IJV). In one embodiment, transcarotid access to the common carotid artery is achieved percutaneously via an incision or puncture in the skin through which the arterial access device 110 is inserted. If an incision is used, the incision length may be about 0.5 cm. An occlusion element 129, such as an expandable balloon, may be used to occlude the common carotid artery (CCA) at a location proximal to the distal end of the arterial access device 110. The occlusion element 129 may be disposed on the arterial access device 110 or on a separate device. In an alternative embodiment, the arterial access device 110 accesses the common carotid artery (CCA) via a direct surgical transcarotid approach. In the surgical approach, a tourniquet 2105 may be used to occlude the common carotid artery. The tourniquet 2105 is shown in phantom to indicate that it is a device used in the optional surgical approach.

[0021] 1B, an arterial access device 110 accesses the common carotid artery (CCA) via a transcarotid approach, while a venous return device 115 accesses a venous return site other than the jugular vein, such as a venous return site consisting of the femoral vein (FV). The venous return device 115 can be inserted into a central vein, such as the femoral vein (FV), via a percutaneous puncture in the groin.

[0022] In another embodiment shown in Figure 1C, the arterial access device 110 accesses the common carotid artery via a femoral approach. According to the femoral approach, the arterial access device 110 approaches the common carotid artery (CCA) via a percutaneous puncture into the femoral artery (FA), such as in the groin, and travels up the aortic arch (AA) to the target common carotid artery (CCA). The venous return device 115 can communicate with the jugular vein (JV) or the femoral vein (FV).

[0023] FIG. 1D illustrates yet another embodiment, in which the retrograde blood flow system 100 provides for backflow from the carotid artery to an external container 130 rather than to a venous return site. The arterial access device 110 is connected to the external container 130 via a shunt 120 in communication with a flow control assembly 125. The backflow of blood is collected in the external container 130. If desired, the blood can be filtered and then returned to the patient. The pressure in the external container 130 may be set to zero pressure (atmospheric pressure) or even lower, allowing blood to flow in a retrograde direction from the cerebral vasculature to the external container 130. Optionally, to achieve or enhance backflow from the internal carotid artery, flow from the external carotid artery can be blocked, usually by placing a balloon or other occlusion element in the external carotid artery just above its bifurcation with the internal carotid artery. Although FIG. 1D illustrates the arterial access device 110 placed in a transcarotid approach via the common carotid artery (CCA), it should be understood that the use of the external container 130 may also be used for the arterial access device 110 in a transfemoral approach.

[0024] 1E illustrates yet another embodiment of a retrograde blood flow system 100. Similar to the previous embodiment, the system includes an arterial access device 110, a shunt 120 with a flow control assembly 125, and a venous return device 115. The arterial access device 110 and the venous return device 115 couple to the shunt 120 at connection locations 127a, 127b. In this embodiment, the flow control assembly also includes an in-line filter, a one-way valve, and a flow control actuator contained within a single flow control housing.

[0025] Referring to the close-up view of the carotid artery in FIG. 2A, an interventional device such as a stent delivery system 135 and / or other working catheter (e.g., a balloon catheter) may be introduced into the carotid artery via the arterial access device 110, as described in more detail below. The stent delivery system 135 may be used to treat the plaque P, such as by deploying a stent in the carotid artery. For example, a stent according to any embodiment disclosed herein (e.g., the embodiment stent 1600 shown in FIGS. 16A-16B, 17A-17B, and 18A-18B of the present disclosure) may be used in the stent delivery system. A balloon catheter may be used, for example, to perform a carotid angioplasty and perform balloon expansion before and / or after stent deployment to assist in the expansion and / or deployment of the stent, as described in more detail below. The arrow RG in FIG. 2A represents the direction of retrograde blood flow.

[0026] 2B illustrates another embodiment in which an arterial access device 110 is used to create an arterial-venous shunt and to introduce at least one interventional device into the carotid artery. A separate arterial occlusion device 112 with an occlusion element 129 may be used to occlude the common carotid artery (CCA) proximal to the distal end of the arterial access device 110.

[0027] 2D illustrates yet another embodiment in which an arterial access device 110 is used to create an arterial-venous shunt and an arterial occlusion using an occlusion element 129 (e.g., an occlusion balloon). A separate arterial introducer device may be used to introduce at least one interventional device into the carotid artery distal to the arterial access device 110.

[0028] <Description of tissue (anatomical structure)> [Collateral cerebral circulation] The Circle of Willis (CW) is the major arterial anastomosis trunk of the brain, connecting all the major arteries supplying blood to the brain, namely the two internal carotid arteries (ICA) and the vertebrobasilar system. Blood is carried from the Circle of Willis to the brain by the anterior, middle, and posterior cerebral arteries. This communication between arteries allows collateral circulation through the brain. It allows blood to flow through alternative routes, thereby providing a safety mechanism in the event that one or more of the blood vessels supplying the brain are occluded. The brain can continue to receive an adequate blood supply in most cases, even if there is an occlusion anywhere in the arterial system (e.g., when the internal carotid artery (ICA) is ligated as described herein). Blood flow through the Circle of Willis ensures adequate cerebral blood flow by multiple pathways that redistribute blood to the deprived side.

[0029] The collateral potential of the Circle of Willis is thought to depend on the presence and size of its constituent vessels. It should be understood that there may be considerable anatomical variation among individuals in these vessels, and many of the involved vessels may be diseased. For example, some individuals may lack one of the communicating arteries. If an occlusion occurs in such an individual, collateral circulation may be compromised, ischemic phenomena may occur, and brain damage may result. Additionally, the autoregulatory response to a drop in perfusion pressure may include enlargement of collateral arteries, such as the communicating arteries of the Circle of Willis. This compensatory mechanism may require time for adjustment before collateral circulation reaches a level that will support normal function. This autoregulatory response may occur over 15-30 seconds and is only compensable within a certain pressure range and within a certain range of flow reduction. Thus, transient ischemic attacks may occur during the adjustment period. Extremely high retrograde flow rates over a prolonged period may result in a condition in which the patient's brain does not receive sufficient blood flow, which may lead to patient intolerance as indicated by neurological symptoms and possibly transient ischemic attacks.

[0030] Figure 4 shows normal cerebral circulation and the formation of the Circle of Willis (CW). The aorta (AO) gives rise to the brachiocephalic artery (BCA), which branches into the left common carotid artery (LCCA) and the left subclavian artery (LSCA). The aorta (AO) further gives rise to the right common carotid artery (RCCA) and the right subclavian artery (RSCA). The left and right common carotid arteries (CCA) give rise to the internal carotid artery (ICA), which branches into the middle cerebral artery (MCA), posterior communicating artery (PCoA), and anterior cerebral artery (ACA). The anterior cerebral artery (ACA) supplies blood to parts of the frontal lobe and the striatum. The middle cerebral artery (MCA) is a large artery with tree-like branches that carry blood throughout the sides of each hemisphere of the brain. The left and right posterior cerebral arteries (PCA) arise from the basilar artery (BA) and send blood to the back of the brain (occipital lobe).

[0031] Anteriorly, the circle of Willis is formed by the anterior cerebral artery (ACA) and the anterior communicating artery (ACoA), which connects the two anterior cerebral arteries (ACA). Two posterior communicating arteries (PCoA) connect the circle of Willis to the two posterior cerebral arteries (PCA) and branch off the basilar artery (BA) to complete the communicating arteries posteriorly.

[0032] The common carotid artery (CCA) also gives rise to the external carotid artery (ECA), which branches extensively to supply most structures of the head except the brain and orbital contents. The ECA also helps supply structures of the neck and face.

[0033] [Carotid artery bifurcation] Figure 5 shows a close-up of the relevant vasculature in the patient's neck. The common carotid artery (CCA) bifurcates at bifurcation B into the internal carotid artery (ICA) and the external carotid artery (ECA). Bifurcation B is located at approximately the level of the fourth cervical vertebra. Figure 5 shows plaque P formed at bifurcation B.

[0034] As described above, the arterial access device 110 may access the common carotid artery (CCA) via a transcarotid approach. According to the transcarotid approach, the arterial access device 110 is inserted into the common carotid artery (CCA) at an arterial access location L. The insertion may be, for example, a surgical incision or puncture of the wall of the common carotid artery (CCA). Typically, there is a distance D of about 5-7 cm between the arterial access location L and the bifurcation B. When the arterial access device 110 is inserted into the common carotid artery (CCA), it is undesirable for the distal tip of the arterial access device 110 to contact the bifurcation B, as this may disrupt plaque P and cause the generation of embolic particles. To minimize the possibility of the arterial access device 110 contacting the bifurcation B, in one embodiment, only about 2-4 cm of the distal region of the arterial access device is inserted into the common carotid artery (CCA) during the procedure.

[0035] The common carotid artery is surrounded on both sides by a layer of fascia called the carotid sheath. The carotid sheath also encases the internal jugular vein and the vagus nerve. Anterior to the carotid sheath is the sternocleidomastoid muscle. Percutaneous or surgical transcarotid access to the common carotid artery and internal jugular vein can be achieved through the carotid sheath just above the clavicle, between the two crests of the sternocleidomastoid muscle, taking care to avoid the vagus nerve.

[0036] At the upper end of the carotid sheath, the common carotid artery branches into the internal and external carotid arteries. The internal carotid artery continues upwards without branching, entering the skull and supplying blood to the retina and brain. The external carotid artery branches to supply blood to the scalp, face, eyeball, and other superficial structures. Several facial and cranial nerves are intertwined before and after the artery. Additional neck muscles may overlap the bifurcation. These nerve and muscle structures can be dissected and pushed aside during carotid endarterectomy to access the carotid bifurcation. In some cases, the carotid bifurcation is closer to the level of the mandible, making access more difficult and leaving less room to separate the bifurcation from the various nerves to be protected. In such cases, the risk of inadvertent nerve injury may be increased, and open endarterectomy may not be a suitable option.

[0037] [Detailed explanation of the retrograde blood flow system] As described above, retrograde blood flow system 100 includes an arterial access device 110, a venous return device 115, and a shunt 120 that provides a pathway for retrograde blood flow from the arterial access device 110 to the venous return device 115. The retrograde blood flow system 100 also includes a flow control assembly 125 that interacts with the shunt 120 to regulate and / or monitor retrograde blood flow through the shunt 120. Exemplary embodiments of components of the retrograde blood flow system 100 will now be described.

[0038] [Arterial access device] FIG. 6A illustrates an exemplary embodiment of an arterial access device 110 including a distal sheath 605, a proximal extension 610, a flow passage 615, an adapter or Y-connector 620, and a hemostasis valve 625. The arterial access device may also include a dilator 645 with a tapered distal end 650 and an introducer guidewire 611. The arterial access device is used with the dilator and introducer guidewire to access the vessel. The functionality of the arterial access device can be optimized for transcarotid access. For example, the design of the access device components can be optimized to limit potential vessel damage from sharp insertion angles, allow for atraumatic and secure sheath insertion, and limit the length of the sheath, sheath dilator, and introducer guidewire inserted into the vessel.

[0039] The distal sheath 605 is configured to be introduced through an incision or puncture in the wall of the common carotid artery, for example, a surgical incision or a percutaneous puncture established using the Seldinger technique. The length of the distal sheath 605 may range from 5 cm to 15 cm, and is typically from 10 cm to 12 cm.

[0040] The inner diameter of the distal sheath 605 is in the range of 7 Fr (1 Fr=0.33 mm) to 10 Fr, and is usually 8 Fr.

[0041] It is desirable for the distal sheath 605 to be highly flexible while maintaining hoop strength to resist kinking and buckling, particularly when the sheath is introduced supraclavicularly and below the carotid bifurcation through a transcarotid approach. Thus, the distal sheath 605 may be circumferentially reinforced by braid, helical ribbon, helical wire, cut tube, or the like, and has an inner liner such that the reinforcement structure is sandwiched between the outer jacket layer and the inner liner. The inner liner may be a low friction material such as PTFE. The outer jacket layer may be one or more of a group of materials including polyether block amide copolymer (Pebax), thermoplastic polyurethane, or nylon. In one embodiment, the reinforcement structure or material, and / or the material or thickness of the outer jacket layer may vary with the longitudinal position of the distal sheath 605, thereby allowing for varying flexibility along the length. In another embodiment, the distal sheath may be configured to be introduced by percutaneous puncture into a femoral artery, such as the groin, and introduced through the aortic arch (AA) to the target common carotid artery (CCA).

[0042] As shown in FIG. 6B (a close-up of the distal region 630 of the distal sheath 605), the distal sheath 605 may have a stepped or other configuration with a reduced diameter distal region 630. The distal region 630 of the sheath may be sized for insertion into the carotid artery and typically has an inner diameter ranging from 0.085 inches to 0.115 inches. The remaining proximal region of the sheath has a larger outer diameter and lumen diameter, with the inner diameter typically ranging from 0.110 inches to 0.135 inches. The larger lumen diameter of the proximal region minimizes the overall flow resistance of the sheath. In one embodiment, the reduced diameter distal region (distal section) 630 has a length of about 2 cm to 4 cm. The relatively short length of the narrowed distal region (distal section) 630 allows this section to be placed in the common carotid artery (CCA) via a transcarotid approach while reducing the risk of the distal end of the distal sheath 605 contacting bifurcation B. Additionally, the narrowed distal region (distal section) 630 also allows for a reduced size of the arteriotomy for introducing the distal sheath 605 into the artery while minimizing the effect on the level of blood flow resistance. Additionally, the narrowed distal region (distal section) 630 may be more flexible, which may allow it to better fit the lumen of the blood vessel.

[0043] 6A, the elongate body proximal extension 610 has a lumen that is continuous with the lumen of the distal sheath 605. The lumens may be joined by a Y-connector 620 that connects the lumen of the flow passage 615 to the sheath.

[0044] In the assembled system, the flow path 615 connects to the reverse flow shunt (shunt 120) forming the first shunt limb of the shunt 120 (see FIG. 1). The proximal extension 610 may be long enough to move the hemostatic valve 625 far enough away from the Y-connector 620 adjacent to the percutaneous or surgical insertion site. By moving the hemostatic valve 625 away from the percutaneous insertion site, the physician can introduce a stent delivery system or other working catheter into the proximal extension 610 and distal sheath 605 while remaining out of the fluoroscopic field of view when a fluoroscopic examination is being performed. In one embodiment, the proximal extension 610 is approximately 16.9 cm from its most distal junction with the distal sheath 605 (e.g., hemostatic valve 625) to the proximal end of the proximal extension 610. In one embodiment, the proximal extension has an inner diameter of 0.125 inches and an outer diameter of 0.175 inches. In one embodiment, the wall thickness of the proximal extension is 0.025 inches. The inner diameter may be, for example, in the range of 0.60 inches to 0.150 inches, and the wall thickness may be, for example, in the range of 0.010 inches to 0.050 inches. In another embodiment, the inner diameter may be, for example, in the range of 0.150 inches to 0.250 inches, and the wall thickness may be, for example, in the range of 0.025 inches to 0.100 inches. The dimensions of the proximal extension may vary. In one embodiment, the proximal extension has a length in the range of about 12 cm to 20 cm. In another embodiment, the proximal extension has a length in the range of about 20 cm to 30 cm.

[0045] In one embodiment, the distance along the sheath from the hemostatic valve 625 to the distal end of the distal sheath 605 is in the range of about 25 cm to 40 cm. In one embodiment, the distance is in the range of about 30 cm to 35 cm. With a system configuration that allows for 2.5 cm sheath introduction into the artery and an arterial distance of 5-10 cm from the arteriotomy site to the target site, the system allows for a distance from the hemostatic valve 625 (location of introduction of the interventional device into the access sheath) to the target site of 32-43 cm, in the range of about 32.5 cm to 42.5 cm. This distance is approximately one-third the distance required by the prior art.

[0046] The flush line 635 can be connected to the side of the hemostasis valve 625 and can have a stopcock 640 at its proximal or distal end. The flush line 635 allows for the introduction of saline, contrast, etc. during the procedure. The flush line 635 can also allow for pressure monitoring during the procedure. A dilator 645 having a tapered distal end 650 may be provided to facilitate the introduction of the distal sheath 605 into the common carotid artery. The dilator 645 can be introduced through the hemostasis valve 625 such that the tapered distal end 650 extends through the distal end of the distal sheath 605 (see FIG. 7A). The dilator 645 can have a central lumen to accommodate a guidewire. Typically, a guidewire is placed in the vessel first, and the dilator / sheath combination travels over the guidewire as it is introduced into the vessel.

[0047] Optionally, as shown in FIG. 7A, a sheath stopper 705, e.g., tubular, coaxially received outside the distal sheath 605 may be provided. The sheath stopper 705 is configured to function as a sheath stopper that prevents the sheath from being inserted too deeply into the blood vessel. The sheath stopper 705 is sized and shaped to be disposed on the sheath body (distal sheath 605) so as to cover a portion of the sheath body (distal sheath 605) and leave a distal portion of the sheath body (distal sheath 605) exposed. The sheath stopper 705 may have a flared proximal end (flange 710) that engages with the adapter (Y connector 620) and a distal end 715. Optionally, the distal end 715 may be configured beveled, as shown in FIG. 7B. The sheath stopper 705 may serve at least two purposes. First, as shown in FIG. 7A, the length of the sheath stopper 705 limits the introduction of the distal sheath 605 to the exposed distal portion of the distal sheath 605 such that the sheath insertion length is limited to the exposed distal portion of the sheath. In one embodiment, the sheath stopper limits the exposed distal portion to a range between 2 cm and 3 cm. In one embodiment, the sheath stopper limited the exposed distal portion to 2.5 cm. In other words, the sheath stopper can limit the insertion of the sheath into the artery to a range between about 2 cm and 3 cm, or up to 2.5 cm. Second, the sheath stopper 705 engages with a pre-deployed puncture closure device (if present) positioned in the carotid artery wall, allowing the distal sheath 605 to be withdrawn without removing the closure device. The sheath stopper 705 may be fabricated from a transparent material such that the sheath body is clearly visible under the sheath stopper 705. The sheath stop 705 may also be made from a flexible material or it may include articulations or portions of increased flexibility to allow the sheath to bend as needed in place once inserted into the artery. The sheath stop may be plastically bendable so that it can be bent into a desired shape by the user and retain that shape when released. The distal portion of the sheath stop may be made from a stiffer material and the proximal portion from a more flexible material.In one embodiment, the harder material is 85A durometer and the softer portion is 50A durometer. In one embodiment, the harder distal portion is 1-4 cm of the sheath stopper 705. The sheath stopper 705 may be removable from the sheath, so that if a user desires a longer sheath insertion, the user can remove the sheath stopper 705, cut it shorter (the length of the sheath stopper), and reassemble the sheath stopper 705 onto the sheath so that a longer insertable sheath length protrudes from the sheath stopper 705.

[0048] FIG. 7C illustrates another embodiment of a sheath stopper 705. The sheath stopper 705 is disposed adjacent to the sheath 605 in which the dilator 645 is disposed. The sheath stopper 705 of FIG. 7C can be transformed from a first shape, such as a straight shape, to a second shape different from the first shape, and the sheath stopper retains the second shape until a sufficient external force acts on the sheath stopper to change shape. The second shape can be, for example, non-straight, curved, or otherwise contoured or irregular. For example, FIG. 7C illustrates a sheath stopper 705 that has multiple bends as well as straight portions. It should be understood that FIG. 7C is merely an example, and the sheath stopper 705 can be formed with any number of bends along its longitudinal axis. FIG. 7D illustrates the sheath stopper 705 disposed on the sheath 605. The sheath stopper 705 has a greater stiffness than the distal sheath 605 such that the distal sheath 605 assumes a shape or contour that matches the contour shape of the sheath stopper 705 .

[0049] The sheath stop 705 can be shaped according to the angle of sheath insertion into the artery and the depth of the artery or the patient's anatomy. This feature reduces the force of the tip of the sheath on the vessel wall, especially when the sheath is inserted into the vessel at a steep angle. The sheath stop can be bent or otherwise deformed into a shape that helps orient the sheath coaxially with the entering artery, even when the angle of entry into the arteriotomy is relatively steep. The sheath stop can be shaped by the operator prior to inserting the sheath into the patient. Alternatively, the sheath stop can be shaped and / or reshaped in situ after the sheath is inserted into the artery. Figures 7E and 7F show an example of the use of a malleable sheath stop 705. Figure 7E shows the sheath stop 705 positioned on the sheath 605 in a straight configuration. The sheath 605 assumes the straight shape of the sheath stop 705 and enters the artery A at a relatively steep angle such that the distal end of the sheath 605 abuts or faces the wall of the artery. In FIG. 7F, the user has bent the sheath stop 705 to adjust the angle of entry of the sheath 605 so that the longitudinal axis of the sheath 605 is more aligned with the axis of the artery A. In this manner, the sheath stop 705 is formed by the user into a shape that helps move the sheath 605 away from the opposing wall of the artery A and more coaxially oriented relative to the axis of the artery A compared to the shape of FIG. 7E.

[0050] In one embodiment, the sheath stopper 705 is made from a malleable material or made of an integral malleable component disposed on or within the sheath stopper. In another embodiment, the sheath stopper is constructed to articulate using an actuator such as a concentric tube, pull wire, or the like. The walls of the sheath stopper may be reinforced with ductile wire or ribbon to help the sheath stopper retain its shape against external forces such as when it encounters a bend in the artery or inlet. Alternatively, the sheath stopper may be constructed of a homogenous malleable tubular material including metals and polymers. The sheath stopper body may be constructed at least in part of a reinforced braid or coil that can retain its shape after deformation.

[0051] Another sheath stop embodiment is configured to facilitate adjustment of the position of the sheath stop (relative to the sheath) even after the sheath is positioned within the vessel. One sheath stop embodiment includes a tube with slits along most or all of its length so that the sheath stop can be peeled away from the sheath body, moved forward or backward as desired, and then repositioned along the length of the sheath body. The tube includes a tab or mechanism at the proximal end so that it can be grasped and more easily peeled away.

[0052] In another embodiment, the sheath stop is a very short tube (such as a band) or ring on the distal section of the sheath body. The sheath stop may include features that allow it to be easily grasped, for example with forceps, and pulled back and forth to a new position as desired to set the appropriate sheath insertion length for the procedure. The sheath stop may be secured to the sheath body by friction from the tubing material or by a clamp that can be opened and closed relative to the sheath body. The clamp may be a spring-loaded clamp that is normally clamped to the sheath body. To move the sheath stop, the user opens the clamp with a finger or an instrument, adjusts the clamp position, and then releases the clamp. The clamp is configured to not interfere with the sheath body.

[0053] In another embodiment, the sheath stop includes a feature that allows the sheath stop and sheath to be sutured to the patient's tissue to improve fixation of the sheath and reduce the risk of sheath dislodgement. This feature may be a suture eyelet attached to or molded into the sheath stopper tube.

[0054] In another embodiment, as shown in FIG. 9A, the sheath stopper 705 includes a distal flange 710 sized and shaped to distribute the force of the sheath stopper over a larger area of ​​the vessel wall, thereby reducing the risk of vessel injury or accidental insertion of the sheath stopper into the vessel through an arteriotomy. The flange 710 may have a round or other atraumatic shape large enough to distribute the force of the sheath stopper over a larger area on the vessel wall. In one embodiment, the flange is inflatable or mechanically expandable. For example, the arterial sheath and sheath stopper may be inserted into the surgical field through a small puncture in the skin and then expanded prior to inserting the sheath into the artery.

[0055] The sheath stopper may include one or more notches or indentations 720 patterned in a staggered configuration along the length of the sheath stopper, such that the indentations increase the flexibility of the sheath stopper while maintaining axial strength to allow forward force of the sheath stopper against the arterial wall. The indentations may also be used to facilitate securing the sheath to the patient via sutures to mitigate sheath dislodgement. The sheath stopper may also include a connector element 730 at the proximal end that corresponds to features of the arterial sheath so that the sheath stopper can be locked or unlocked to the arterial sheath. For example, the connector element may be a hub with a generally L-shaped slot 740 that corresponds to a pin 750 on the hub, creating a bayonet mount style connection. In this manner, the sheath stopper may be securely attached to the hub, reducing the likelihood of the sheath stopper being inadvertently removed from the hub unless unlocked from the hub.

[0056] The distal sheath 605 may be configured to establish a curvilinear transition from a generally anterior-posterior approach on the common carotid artery to a generally luminal axial approach within the common carotid artery. Arterial access through the common carotid artery wall, either by direct surgical incision or percutaneous access, may typically require a larger access angle than other arterial access sites. This is due to the fact that the common carotid artery insertion site is much closer to the treatment site (the carotid bifurcation) than other access points. A larger access angle is required to increase the distance from the insertion site to the treatment site so that the sheath can be inserted the appropriate distance without the distal end of the sheath reaching the carotid bifurcation. For example, for transcarotid access, the sheath insertion angle is typically 30-45 degrees or more, and for femoral artery access, the sheath insertion angle may be 15-20 degrees. Thus, the sheath must bend more than typically performed with an introducer sheath without kinking or exerting excessive force on the opposing arterial wall. Additionally, it is desirable for the tip of the sheath not to abut or contact the arterial wall in a manner that would restrict flow into the sheath after insertion. The insertion angle of the sheath is defined as the angle between the lumen axis of the artery and the longitudinal axis of the sheath.

[0057] The sheath body (distal sheath 605) can be shaped in a variety of ways to allow for this large bending required by the access angle. For example, the sheath and / or dilator may have a lower bending stiffness than a typical introducer sheath. In one embodiment, the sheath and dilator combination (i.e., the sheath with the dilator disposed therein) has a bending stiffness of approximately 80-100 N·m 2 ×10 -6 The sheath has a bending stiffness (E×I) in the range of 30 to 40 N m. Here, E is the Young's modulus (elastic modulus) and I is the area moment of inertia of the device. The bending stiffness of the sheath alone is approximately 30 to 40 N m. 2 ×10 -6 The bending stiffness of the expander alone is in the range of 40 to 60 N·m 2 ×10 -6 The bending stiffness of a typical sheath and dilator combination is in the range of 150 to 250 N·m2 ×10 -6 The sheath 605 may be preformed to have a curved or bent portion (angle portion) at a certain distance (typically 0.5-1 cm) from the tip. The preformed curved or bent portion may provide a change in direction, typically in the range of 5°-90°, and preferably in the range of 10°-30°. For example, the sheath may have a ribbon coil reinforcement of stainless steel. The ribbon coil reinforcement may have a thickness of 0.002-0.003 inches, a width of 0.005-0.015 inches, and an outer jacket hardness (durometer) of 40-55D. In one embodiment, the ribbon coil reinforcement may have a thickness of 0.003 inches, a width of 0.010 inches, and an outer jacket hardness (durometer) of 45D. In one embodiment, the sheath 605 may be preformed to have a curved or bent portion (angle portion) at a certain distance (typically 0.5-1 cm) from the tip. The preformed curved or bent portion may provide a change in direction, typically in the range of 5°-90°, and preferably in the range of 10°-30°. Initially during introduction, the sheath 605 is straightened by an obturator or other straight or shaped device (e.g., dilator 645) placed within its lumen. After the sheath 605 has been introduced at least partially through a percutaneous or other arterial wall penetration, the obturator may be withdrawn, causing the sheath 605 to resume its preformed configuration in the arterial lumen. To maintain the curved or bent shape of the sheath body after straightening during insertion, the sheath may be heat set into the curved or bent shape during manufacture. Alternatively, the reinforcing structure may be constructed from Nitinol and heat formed into the curved or bent shape during manufacture. Alternatively, additional spring elements may be added to the sheath body, for example, strips of spring steel or Nitinol may be added to the reinforcing layer of the sheath in the correct shape.

[0058] Other sheath configurations may include having a mechanism whereby the sheath is positioned and the catheter is deflected in situ to a desired deployment angle. In yet other configurations, the catheter is in a soft configuration when placed within the lumen of the common carotid artery. Once in place, pull wires or other stiffening mechanisms may be deployed to shape and stiffen the sheath into a desired configuration. Certain examples of such mechanisms are commonly known as "shape-lock" mechanisms, as described in the medical and patent literature.

[0059] Another sheath configuration includes a curved dilator inserted into a straight, yet flexible, sheath, where the dilator and sheath curve during insertion, and the sheath remains flexible enough to conform to the anatomy after removal of the dilator.

[0060] Another sheath embodiment is a sheath that includes one or more flexible distal sections. Once inserted into an angled configuration, the sheath can bend at large angles without kinking and without exerting excessive force on the opposing arterial wall. In one embodiment, the distal-most section of the sheath body (distal sheath 605) is more flexible than the remainder of the sheath body. For example, the bending stiffness of the distal-most section is half to one-tenth the bending stiffness of the remainder of the sheath body (distal sheath 605). In one embodiment, the bending stiffness of the distal-most section is between 30 and 300 N·mm 2 , and the bending stiffness of the remaining part of the sheath body (distal sheath 605) is in the range of 500 to 1500 N·mm 2For a sheath configured for a common carotid artery (CCA) access site, the flexible most distal section constitutes a significant portion of the sheath body 222, which may be expressed as a ratio. In one embodiment, the ratio of the length of the flexible most distal section to the overall length of the sheath body 222 is at least one tenth and at most one half of the overall length of the sheath body 222. Such a change in flexibility may be achieved in a variety of ways. For example, the outer jacket may vary in hardness (durometer) or material in multiple sections. Alternatively, the reinforcing structure or material may vary over the entire length of the sheath body. In one embodiment, the flexible most distal section is in the range of 1 cm to 3 cm. In an embodiment with multiple sections of differing flexibility, the less flexible section (relative to the distal most section) may be 1 cm to 2 cm away from the distal most section. In one embodiment, the bending stiffness of the flexible most distal section is about 30 to 50 N·m 2 ×10 -6 and the bending stiffness of the less flexible sections is approximately 50-100 N m 2 ×10 -6In another embodiment, the more flexible section is placed between 0.5-1.5 cm and 1-2 cm in length. This creates an articulating section that allows the distal section of the sheath to be more easily aligned with the axis of the vessel, even if the sheath enters the artery at an angle. These configurations with multiple sections of differing flexibility can be manufactured in several ways. For example, the reinforced less flexible section may vary with a stiff reinforcement in the proximal section and a softer reinforcement in the distal or articulating section. In one embodiment, the outermost jacket material of the sheath is 45D-70D hardness (durometer) in the proximal section and 80A-25D hardness (durometer) in the most distal section. In one embodiment, the flexibility of the sheath varies continuously along the length of the sheath body. FIG. 7G shows such a sheath inserted into an artery, where the flexible distal section allows the sheath body to bend and the distal tip to be approximately aligned along the vessel lumen. In one embodiment, the distal section is made with a softer reinforcement structure by varying the pitch of the coil or braid or by incorporating cut hypotubes with a different cut pattern, or the distal section has a different reinforcement structure than the proximal section.

[0061] In one embodiment, the tapered tip of the distal sheath is manufactured from a harder material than the distal sheath body. The purpose of this is to provide a very smooth taper to the sheath to facilitate insertion of the sheath and reduce distortion and ovalization changes at the sheath tip during and after insertion into the vessel. In one example, the material of the tapered tip of the distal sheath is manufactured from a material with a high hardness (e.g., 60-72D Shore D). In another example, the tapered tip of the distal sheath is manufactured from another material (e.g., high density polyethylene (HDPE), stainless steel, or other suitable polymers or metals). In a further embodiment, the tapered tip of the distal sheath is manufactured from a radiopaque material, either as an additive to the polymeric material (e.g., tungsten or barium sulfate) or as an inherent property of the material (in the case of most metallic materials).

[0062] In another embodiment, the dilator 645 may have variable stiffness. For example, the tapered distal end 650 of the dilator may be made of a more flexible material than the proximal portion of the dilator to minimize the risk of injury to the blood vessel when the sheath and dilator are inserted into the artery. In one embodiment, the bending stiffness of the flexible distal section is about 45-55 N·m 2 ×10 -6 and the bending stiffness of the less flexible proximal section is approximately 60–90 N m 2 ×10 -6 The taper of the dilator may be optimized for transcarotid access. For example, to limit the amount of sheath and dilator tip entering the artery, the length of the taper and the amount of dilator extending beyond the sheath should be shorter than a typical introducer sheath. For example, the taper length is 1-1.5 cm and extends 1.5-2 cm from the end of the sheath body. In one embodiment, the distal end of the dilator includes a radiopaque marker, which allows the location of the tip to be easily visualized under fluoroscopy.

[0063] In another embodiment, the introducer guidewire is optimally configured for transcarotid access. Typically, when an introducer sheath is inserted into a blood vessel, the introducer guidewire is inserted into the blood vessel first. This insertion may be performed by either the micropuncture method or the modified Seldinger technique. Typically, there is a long blood vessel in the direction in which the sheath is inserted, and the introducer guidewire may be inserted into that blood vessel (e.g., the femoral artery). In this case, the user may insert the guidewire into the blood vessel 10 to 15 cm or more before inserting the sheath. The guidewire is designed to have a flexible distal section so as not to damage the blood vessel when it is introduced into the artery. The length of the flexible distal section of the introducer guidewire is usually 5 to 6 cm, and gradually transitions to a hard section. When the guidewire is inserted 10 to 15 cm, the hard section of the guidewire is positioned at the puncture site, and can stably support the subsequent insertion of the sheath and dilator into the blood vessel. However, in the case of transcarotid sheath insertion into the common carotid artery, there is a limit to the length of the guidewire that can be inserted into the carotid artery. In cases where there is carotid disease at the bifurcation or internal carotid artery, it is desirable to minimize the risk of embolism by inserting the guidewire into the external carotid artery (ECA). In this case, the guidewire insertion is only about 5-7 cm. Alternatively, it is desirable to stop the guidewire before reaching the bifurcation and limit the guidewire insertion to 3-5 cm. This may result in a transcarotid sheath guidewire with a 3-4 cm flexible distal section and / or a short transition to a stiffer section. Alternatively, the transcarotid sheath guidewire may have an atraumatic tip but a very distal and short transition to the stiffer section. For example, the flexible tip may be 1.5-2.5 cm, followed by a transition section 3-5 cm long, followed by a stiff proximal section that constitutes the remainder of the wire.

[0064] In addition to the above configurations, the introducer guidewire, the small puncture catheter, or the small puncture catheter guidewire may include features to prevent these devices from being inadvertently advanced into the diseased portion of the carotid artery. For example, a stop feature may be placed on the introducer guidewire, the small puncture catheter, and / or the small puncture guidewire, which may limit the length to which these devices can be inserted. The stop feature may be, for example, a short tube section that is slidably placed on the device and, once placed, remains in place on the device by friction. For example, the stop feature may be fabricated from a soft polymeric material (e.g., silicone rubber, polyurethane, or other thermoplastic elastomer). The inner diameter of the stop feature may be the same size as or slightly smaller than the diameter of the device. Alternatively, the stop feature may be configured to be clamped to the device. In this case, the user must squeeze or unlock the stop feature to unclamp and reposition the device, and then move the stop feature away from the device and relock it. The stop feature can be positioned for optimal entry into the vessel based on the location of the puncture site, the distance of the bifurcation to the puncture site, and the extent of disease at the carotid bifurcation.

[0065] The sheath guidewire may be provided with guidewire markers to help the user determine where the tip of the wire is relative to the dilator. For example, a marker may be placed on the proximal end of the wire that corresponds to when the tip of the wire is about to exit the tip of the microaccess cannula. This marker provides immediate feedback on the position of the wire and allows the user to limit the amount of wire insertion. In another embodiment, the wire may include an additional marker to inform the user when the wire has exited the cannula a set distance (e.g., 5 cm). Alternatively, the introducer guidewire, small puncture catheter, and / or small puncture guidewire may be constructed from or have sections constructed from a material that can be marked with a marking pen. In this case, the markings are easily visible in the catheter lab or operating room (OR) environment. In this embodiment, the user pre-marks the components based on anatomical information as described above and uses these marks to determine the maximum insertion amount of each component. For example, the guidewire may be provided with a white coating around the area to be marked.

[0066] In one embodiment, the sheath may incorporate puncture capability and an atraumatic tip similar to that of a guidewire, eliminating the need for needle and wire exchanges currently used for micropuncture arterial access, saving time, reducing blood loss, and reducing the need for surgeon skill.

[0067] In another embodiment, the sheath dilator is configured to be inserted over a 0.018 inch guidewire for transcarotid access. Standard sheath insertion using a micropuncture kit requires first inserting a 0.018 inch guidewire through a 22 Ga needle, then exchanging the guidewire for a 0.035 inch or 0.038 inch guidewire using a micropuncture catheter, and finally inserting the sheath and dilator over the 0.035 inch or 0.038 inch guidewire. Sheaths exist that are insertable over 0.018 inch guidewires, eliminating the need for wire exchange. These sheaths are usually labeled "transradial" because they are designed for insertion into the radial artery, and usually have a longer dilator taper to allow for an appropriate increase in diameter from the 0.018 inch wire to the sheath body. Unfortunately, for transcarotid access, these existing sheaths are not suitable because the insertion length of the sheath and dilator is limited. Another drawback is that a 0.018 inch guidewire may not provide the support necessary to insert a sharp-angled sheath into the carotid artery. In an embodiment disclosed herein, a transcarotid sheath system includes a sheath body, a sheath expander, and an inner tube with a tapered distal end. The inner tube fits slidably within the sheath expander and may accommodate a 0.018 inch guidewire.

[0068] To use the sheath system of this embodiment, a 0.018 inch guidewire is first inserted through the 22 Ga needle into the vessel. The coaxially assembled sheath system is then inserted over the 0.018 inch wire. The inner tube is first advanced over the 0.018 inch wire, essentially converting it to the equivalent of a 0.035 inch or 0.038 inch guidewire in both outer diameter and mechanical support. The inner tube is secured to the 0.018 inch wire at its proximal end. The sheath and dilator are then advanced into the vessel over the 0.018 inch wire and inner tube. This configuration does not require a long dilator taper as with current transradial sheaths, and uses the same guidewire support as a standard introducer sheath, eliminating the need for a wire exchange procedure. As previously mentioned, the sheath system of this configuration may include a stop feature to prevent the 0.018 inch guidewire or inner tube from being inadvertently advanced too far during sheath insertion. Once the sheath is inserted, the dilator, inner tube, and 0.018 inch guidewire are removed.

[0069] FIG. 8A illustrates another embodiment of an arterial access device 110. This embodiment is substantially similar to the embodiment illustrated in FIG. 6A, except that the distal sheath 605 includes an occlusion element 129 for occluding flow through, for example, the common carotid artery. If the occlusion element 129 is an inflatable structure, such as an occlusion balloon, the sheath 605 may include an inflation lumen in communication with the occlusion element 129. The occlusion element 129 may be an inflatable occlusion balloon, but may also be an inflatable cuff, a cone-shaped or other shaped peripheral element that expands radially outward to engage the inner wall of the common carotid artery and block flow therethrough, a membrane-covered braid, a slotted tube that expands when axially compressed, or similar structure that may be deployed by mechanical means. In the case of balloon occlusion, the occlusion balloon may be compliant, non-compliant, elastic, high strength, or have a variety of other properties. In one embodiment, the occlusion balloon is an elastic balloon that fits closely around the circumference of the distal end of the sheath prior to inflation. Upon inflation, the elastic occlusion balloon expands and fits snugly against the inner wall of the common carotid artery. In one embodiment, the elastic occlusion balloon is expandable to at least twice its diameter compared to its undeployed configuration, often to at least three times its diameter, and more preferably to at least four times its diameter or more.

[0070] As shown in FIG. 8B, the distal sheath 605 with the occlusion element 129 may have a stepped or other configuration with a reduced diameter distal region 630. The distal region 630 is sized to be inserted into the carotid artery, while the remaining proximal region of the sheath 605 has a larger outer diameter and inner lumen diameter. The inner diameter of the remaining proximal region of the sheath 605 typically ranges from 0.110 inches to 0.135 inches. The larger lumen diameter of the proximal region minimizes the overall flow resistance of the sheath. In one embodiment, the reduced diameter distal region 630 is approximately 2 cm to 4 cm in length. The relatively short length of the reduced diameter distal region 630 allows this section to be placed into the common carotid artery (CCA) via a transcarotid approach, reducing the risk of the distal end of the sheath 605 contacting the bifurcation B.

[0071] FIG. 2C illustrates an alternative embodiment, in which an occlusion element 129 may be introduced into the carotid artery on a second sheath (arterial occlusion device 112) separate from the distal sheath 605 of the arterial access device 110. The second or "proximal" sheath (arterial occlusion device 112) may be configured to be inserted into the common carotid artery in a proximal or "downward" direction away from the cerebral vasculature. The second or proximal sheath (arterial occlusion device 112) may include an inflatable occlusion balloon or other occlusion element (occlusion element 129), generally as described above. The distal sheath 605 of the arterial access device 110 may then be placed into the common carotid artery distal to the second or proximal sheath and generally oriented distally toward the cerebral vasculature. The use of separate occlusion and access sheaths may reduce the size of the arteriotomy required for introduction of the access sheath.

[0072] 2D illustrates yet another embodiment of a dual arterial sheath system in which an interventional device is introduced through an introducer sheath 114 that is separate from the distal sheath 605 of the arterial access device 110. The second or "distal" sheath 114 may be configured for insertion into the common carotid artery distal to the arterial access device 110. As with the previous embodiment, the use of two separate access sheaths may reduce the size of each arteriotomy.

[0073] When the sheath is inserted at an acute angle, such as in a transcarotid access procedure, and / or when the length of the sheath inserted into the artery is short, the distal end of the sheath is likely to partially or completely impinge on the vessel wall, thereby restricting flow into the sheath. In one embodiment, the sheath is configured to center its tip in the lumen of the vessel. One such embodiment includes an occlusion balloon, such as the occlusion element 129 described above. In another embodiment, the balloon does not occlude flow, such as an inflatable bumper, but can still center the tip of the sheath away from the vessel wall. In another embodiment, an expandable feature is located at the tip of the sheath and is mechanically expanded once the sheath is in place. Examples of mechanically expandable features include braided structures, helical structures, or longitudinal struts that radially expand when foreshortened.

[0074] In one embodiment, occlusion of the vessel proximal to the distal end of the sheath may be performed from outside the vessel, such as, for example, a Rummel tourniquet or vessel loop proximal to the sheath insertion site. In another embodiment, an occlusion device may be attached to the exterior of the vessel around the sheath tip, such as an elastic loop, an inflatable cuff, or a mechanical clamp that may be tightened around the vessel and the distal sheath tip. In a retrograde blood flow system, such a vessel occlusion method minimizes static blood flow regions and reduces the risk of thrombus formation. It also ensures that the tip of the sheath is axially aligned with the vessel and is not partially or completely blocked by the vessel wall.

[0075] In one embodiment, side holes may be provided in the distal portion of the sheath body to maintain flow into the sheath even if the tip of the sheath becomes partially or completely blocked by the arterial wall.

[0076] Another arterial access device is shown in Figures 9A-9D. In this configuration, the method of connection to the shunt is different from the configuration described above. Figure 9A shows the components of the arterial access device 110, including the arterial access sheath (distal sheath 605), sheath dilator 645, sheath stopper 705, and sheath guidewire 111. Figure 9B shows the arterial access device 110 assembled for insertion into the carotid artery over the sheath guidewire 611. After the sheath is inserted into the artery, the sheath guidewire 611 and sheath dilator 645 are removed during the procedure. In this configuration, the sheath has a sheath body (distal sheath 605), a proximal extension 610, and a proximal hemostatic valve 625 with a flush line 635 and a stopcock 640. The proximal extension 610 extends from the Y-adapter 660 to the hemostatic valve 625 to which the flush line 635 is connected. The sheath body (distal sheath 605) is sized so that it can be inserted into the carotid artery, and is the part that is actually inserted into the artery during use.

[0077] Instead of a Y-connector with a fluid connection terminating in a valve, the sheath is provided with a Y-adapter 660 that connects the distal portion of the sheath to the proximal extension 610. The Y-adapter may also include a valve 670 operable to open or close a fluid connection to a connector or hub 680 that may be removably connected to a fluid path such as a shunt. The valve 670 is located immediately adjacent to the lumen of the adapter 660 that communicates with the lumen of the sheath body (distal sheath 605). Figures 9C and 9D show a cross-sectional detail of the Y-adapter 660 with the valve 670 and hub 680. Figure 9C shows the valve closed relative to the connector. The position of the valve in Figure 9C is during preparation of the arterial sheath. The valve is configured to prevent the possibility of air being trapped during preparation of the sheath. Figure 9D shows the valve open relative to the connector. The position of Figure 9D is used when the shunt 120 is connected to the hub 680, allowing blood flow from the arterial sheath to the shunt. This configuration eliminates the need to prime both a flush line and a flow path, instead allowing for preparation from a single flush line 635 and stopcock 640. This single point preparation is more familiar and convenient for the user as it is the same as preparation of a traditional introducer sheath with no connection to a shunt line. Additionally, the lack of a flow path in the sheath allows for easier handling during preparation of the arterial sheath and insertion into the artery.

[0078] 9A, the sheath may also include a more distal second connector 690 separated from the Y adapter 660 by a segment of tubing 665. The purpose of this second connector 690 and tubing 665 is to allow the valve 670 to be placed further proximally from the distal end of the sheath while limiting the length of the insertable portion of the sheath 605, thereby reducing the user's exposure to the radiation source when the shunt is connected to the arterial sheath during the procedure. In one embodiment, the distal connector (second connector 690) includes a suture eyelet that helps secure the sheath to the patient after placement.

[0079] [Venous return device] 10, the venous return device 115 may include a distal sheath 910 and a flow channel 915 that connects to the shunt 120 to form the shunt limb of the shunt 120 when the system is in use. The distal sheath 910 is configured to be introduced into a venous return location, such as the jugular or femoral vein, through an incision or puncture. The distal sheath 910 and the flow channel 915 may be permanently attached or may be attached using a conventional luer fitting, as shown in FIG. 10A. Optionally, as shown in FIG. 10B, the distal sheath 910 may be coupled to the flow channel 915 by a Y-connector 1005. The Y-connector 1005 may include a hemostasis valve 1010. The venous return device also includes a venous sheath expander 1015 and an introducer guidewire 611 to facilitate introduction of the venous return device into the internal jugular or other vein. Similar to the arterial access dilator (dilator 645), the venous sheath dilator 1015 includes a central guidewire lumen so that a venous sheath and dilator combination may be placed over the guidewire 611. Optionally, the venous sheath (distal sheath 910) may include a flush line 1020 with a stopcock 1025 at its proximal or distal end.

[0080] An alternative configuration is shown in Figures 10C and 10D. Figure 10C shows the components of the venous return device 115, including the venous return sheath (distal sheath) 910, the venous sheath dilator 1015, and the sheath guidewire 611. Figure 10D shows the venous return device 115 assembled for insertion over the sheath guidewire 611 into a central vein. Once the sheath is inserted into the vein, the dilator and guidewire are removed. The venous sheath may include a hemostatic valve 1010 and a flow channel 915. A stopcock 1025 at the end of the flow channel allows the venous sheath to be flushed through the flow channel prior to use. This configuration allows the sheath to be prepared from a single point, similar to a conventional introducer sheath. Connection to the shunt 120 is made using a connector 1030 on the stopcock 1025.

[0081] To reduce flow resistance throughout the system, the arterial access channel 615 (FIG. 6A) and the venous return channel 915, as well as the Y-connector 620 (FIG. 6A) and the Y-connector 1005, may each have a relatively large inner diameter (typically in the range of 0.100 inches to 0.200 inches) and a relatively short length (usually in the range of 10 cm to 20 cm). Low flow resistance in the system is desirable because it can maximize flow during the portion of the procedure where the risk of emboli is highest. Low flow resistance in the system also allows for the use of variable flow resistance to control flow within the system, as described in more detail below. The dimensions of the venous return sheath (distal sheath) 910 may be approximately the same as those described for the arterial access sheath (distal sheath 605) above. An extension of the hemostatic valve 1010 is not required in the venous return sheath.

[0082] [Reflux shunt] The shunt 120 may be formed of a single tube or multiple connected tubes that provide fluid communication between the arterial access device 110 (arterial access catheter) and the venous return catheter (venous return device 115) and provide a path for retrograde blood flow therebetween. As shown in FIG. 1A, the shunt 120 connects at one end (via a connector at connection location 127a) to a flow path 615 of the arterial access device 110 and at the other end (via a connector at connection location 127b) to a flow path 915 of the venous return catheter (venous return device 115).

[0083] In one embodiment, the shunt 120 may be formed of at least one tube in communication with the flow control assembly 125. The shunt 120 may have any structure that provides a fluid pathway for blood flow. The shunt 120 may have a single lumen or multiple lumens. The shunt 120 may be removably attached to the flow control assembly 125, the arterial access device 110, and / or the venous return device 115. Prior to use, a user may select a length of the shunt 120 that is most suitable for use at the arterial access and venous return locations. In one embodiment, the shunt 120 may include one or more extension tubes that can be used to vary the length of the shunt 120. The extension tubes may be modularly attached to the shunt 120 to achieve a desired length. The modular nature of the shunt 120 allows a user to lengthen the shunt 120 as needed depending on the venous return site. For example, some patients may have small and / or tortuous internal jugular veins (IJVs). This site may be at higher risk of complications than other sites due to its proximity to other anatomical structures. Furthermore, hematomas in the neck may lead to airway obstruction and cerebrovascular complications. Therefore, for such patients, it may be desirable to place a venous return site at a location other than the internal jugular vein (IJV), such as the femoral vein. A femoral venous return site can be performed percutaneously, which has a lower risk of serious complications, and also provides alternative venous access to central veins when the IJV is unavailable. Furthermore, femoral venous return changes the layout of the retrograde shunt, allowing the shunt control device to be located closer to the interventional "working area" where the device is introduced and the contrast injection port is placed.

[0084] In one embodiment, the shunt 120 has an inner diameter of 4.76 mm (3 / 16 inches) and a length of 40-70 cm. As previously mentioned, the length of the shunt is adjustable. In one embodiment, the connectors between the shunt and the arterial access device and / or venous access device are configured to minimize flow resistance. In one embodiment, the arterial access sheath (arterial access device 110), the reflux shunt (shunt 120), and the venous return sheath (venous return device 115) are combined to create a low flow resistance arterial venous shunt (AV shunt) as shown in Figures 1A-1D. As previously mentioned, the connections and flow paths of all these devices are optimized to minimize or reduce flow resistance. In one embodiment, the AV shunt has a flow resistance that allows a maximum of 300 mL / min flow when no device is present in the arterial access device 110 (arterial access sheath) and the AV shunt is connected to a fluid source with blood viscosity and a static pressure head of 60 mmHg. The actual shunt resistance varies depending on the presence or absence of a check valve (valve 1115) and filter 1145 (see FIG. 11) and the length of the shunt, and may allow a flow rate of 150 to 300 mL / min.

[0085] When a device such as a stent delivery catheter is present within the arterial sheath, the flow resistance increases in a portion of the arterial sheath, thus increasing the flow resistance throughout the AV shunt. This increased flow resistance results in a corresponding decrease in flow. In one embodiment, a Y-arm (Y-connector 620) as shown in FIG. 6A connects the arterial sheath body (distal sheath 605) to a flow path 615 some distance from a hemostasis valve 625 where the catheter is introduced into the sheath. This distance is set by the length of the proximal extension 610. Thus, the portion of the arterial sheath restricted by the catheter is limited to the length of the sheath body (distal sheath 605). The actual flow restriction depends on the length and inner diameter of the sheath body (distal sheath 605) and the outer diameter of the catheter. As mentioned above, the length of the sheath ranges from 5 cm to 15 cm, typically 10 cm to 12 cm, and the inner diameter typically ranges from 7 Fr (1 Fr=0.33 mm) to 10 Fr, typically 8 Fr. Stent delivery catheter sizes may range from 3.7 Fr to 5.0 Fr, or 3.7 Fr to 6.0 Fr, depending on the stent size and manufacturer. This limitation can be further alleviated by designing the non-intravascular portion of the sheath body (the stepped sheath body) to have a larger inner diameter, as shown in Figure 6B. Because flow restriction is proportional to the fourth power of the lumen distance, a small increase in lumen or annular area will result in a large decrease in flow resistance.

[0086] When an arteriovenous shunt (AV shunt) is used, the actual flow rate of the AV shunt further depends on the patient's cerebral blood pressure and flow resistance.

[0087] [Flow Control Assembly (Adjustment and monitoring of retrograde blood flow)] The flow control assembly 125 interacts with the retrograde shunt (shunt 120) to regulate and / or monitor the rate of retrograde blood flow from the common carotid artery to a venous return site (e.g., femoral vein, internal jugular vein) or to an external reservoir 130. In this regard, the flow control assembly 125 allows a user to achieve a higher maximum flow rate than existing systems, and also to selectively adjust, set, or regulate the rate of retrograde blood flow. As described in more detail below, various mechanisms may be used to regulate the rate of retrograde blood flow. The flow control assembly 125 allows a user to configure the retrograde blood flow in a manner suitable for various treatment regimens, as described below.

[0088] Generally, the ability to control the continuous retrograde blood flow rate allows the physician to tailor the procedure to the individual patient and stage of the procedure. The retrograde blood flow rate is typically controlled over a range from low to high. The high rate can be at least twice the low rate, typically is at least three times the low rate, and often is at least five times or more the low rate. In one embodiment, the high rate is at least three times higher than the low rate, and in another embodiment, the high rate is at least six times higher than the low rate. Although a high retrograde blood flow rate is generally desirable to maximize the removal of emboli from the carotid artery, patients have different tolerances to retrograde blood flow. Thus, a system and protocol that allows for easy adjustment of the retrograde blood flow rate would allow the treating physician to determine if the blood flow rate exceeds the patient's tolerance level and set the retrograde blood flow rate accordingly. For patients who cannot tolerate continuous high retrograde blood flow rates, physicians can choose to turn on high flow rates only for short, critical portions of the procedure, when the risk of embolic debris is highest. Short intervals, such as 15 seconds to 1 minute, do not usually take into account the patient's tolerance limits.

[0089] In certain embodiments, the flow rate of continuous retrograde blood flow may be controlled at a baseline flow rate (basal flow rate) ranging from 10 ml / min to 200 ml / min, typically 20 ml / min to 100 ml / min. These flow rates will be tolerable to the majority of patients. For the majority of procedures, the flow rate is maintained at the baseline flow rate, but when the risk of emboli release increases, the flow rate may be elevated above the baseline for a short period of time to improve the ability to capture such emboli. For example, the flow rate of retrograde blood flow may be elevated above the baseline during introduction of a stent catheter, during deployment of a stent, before and after expansion of a stent, during removal of a common carotid artery occlusion, etc.

[0090] The flow control system may be cycled between a relatively low flow rate and a relatively high flow rate to "flush" the carotid artery at the carotid bifurcation before re-establishing antegrade blood flow. Such cycling may be established at a high flow rate that is about 2-6 times, usually about 3 times, the low flow rate. The length of one cycle of cycling ranges from 0.5 seconds to 10 seconds, usually 2 seconds to 5 seconds, and the total duration of cycling ranges from 5 seconds to 60 seconds, usually 10 seconds to 30 seconds.

[0091] 11 illustrates an example of the system 100 and a schematic diagram of a flow control assembly 125. The flow control assembly 125 is positioned along the shunt 120 such that retrograde blood flow passes through or communicates with at least a portion of the flow control assembly 125. The flow control assembly 125 may include various controllable mechanisms for regulating and / or monitoring retrograde blood flow. The mechanisms may include, for example, one or more pumps 1110, valves 1115, syringes 1120, and / or variable flow resistance components 1125 as various means for controlling retrograde blood flow. The flow control assembly 125 may be manually controlled by a user or automatically controlled via a controller 1130 to vary the flow through the shunt 120. For example, by varying the flow resistance, the rate of retrograde blood flow through the shunt 120 may be controlled. The controller 1130, which will be described in more detail below, may be integrated into the flow control assembly 125 or may be a separate component in communication with components of the flow control assembly 125.

[0092] Additionally, the flow control assembly 125 may include one or more flow sensors 1135 and / or anatomical data sensors 1140 (described in more detail below) for sensing one or more aspects of retrograde blood flow. A filter 1145 may be positioned along the shunt 120 to remove emboli before blood is returned to the venous return site. If the filter 1145 is positioned upstream of the controller 1130, the filter 1145 may prevent blood clots from entering the controller 1130 and potentially clogging the variable flow resistance component 1125. It should be noted that the various components of the flow control assembly 125 (including the pump 1110, the valve 1115, the syringe 1120, the variable flow resistance component 1125, the sensors 1135, 1140, and the filter 1145) may be positioned at various locations along the shunt 120 and upstream or downstream relative to one another. The locations of the components of the flow control assembly 125 are not limited to the locations shown in FIG. 11. Additionally, flow control assembly 125 may not necessarily include all of the components, but rather may include various subcombinations of components. For example, a syringe may optionally be used within flow control assembly 125 for purposes of regulating flow, or may be used external to the assembly for purposes other than flow regulation, such as introducing a fluid, such as a radiopaque contrast agent, into an artery in the antegrade direction through shunt 120.

[0093] Both the variable flow resistance component 1125 and the pump 1110 may be connected to the shunt 120 to control the rate of retrograde blood flow. The variable flow resistance component 1125 controls the flow resistance, and the pump 1110 provides a positive displacement of blood through the shunt 120. That is, rather than relying on the perfusion stump pressures in the external carotid artery (ECA) and internal carotid artery (ICA) and venous back pressure to drive retrograde blood flow, the pump may be actuated. The pump 1110 may be a peristaltic tube pump or any type of pump, including a positive displacement pump. The pump 1110 may be started and stopped (manually or automatically via the controller 1130) to selectively achieve the movement of blood through the shunt 120 and control the flow rate through the shunt 120. The movement of blood through the shunt 120 may be achieved in other ways, including the use of the suction syringe 1120, or a suction source (e.g., a vacutainer, a backlock syringe, or a wall suction, etc.) may be used. The pump 1110 is in communication with a controller 1130 .

[0094] One or more flow control valves 1115 may be positioned along the shunt pathway. The valves may be manually or automatically actuated (via controller 1130). The flow control valves 1115 may be, for example, one-way valves that prevent antegrade flow through the shunt 120, check valves, or high pressure valves that close the shunt 120, for example, during high pressure contrast injections (injections intended to enter the arterial vasculature in the antegrade direction). In one embodiment, the one-way valves are low flow resistance valves, such as those disclosed in U.S. Pat. No. 5,727,594, or other low resistance valves.

[0095] In embodiments of the shunt that include both a filter 1145 and a one-way check valve (flow control valve 1115), the one-way check valve (flow control valve 1115) is located downstream of the filter 1145. In this embodiment, if there is debris traveling through the shunt, it is captured by the filter 1145 before it reaches the one-way check valve (flow control valve 1115). Many check valve configurations include a seal member that seals against a housing that contains the flow passage (flow lumen). Debris can become trapped between the seal member and the housing, compromising the valve's ability to seal against reverse pressure.

[0096] The controller 1130 can communicate with components of the system 100, including the flow control assembly 125, to enable manual and / or automatic adjustment and / or monitoring of retrograde blood flow through the components of the system 100 (e.g., including the shunt 120, the arterial access device 110, the venous return device 115, and the flow control assembly 125). For example, a user can actuate one or more actuators on the controller 1130 to manually control the components of the flow control assembly 125. Manual controls may include switches, dials, or similar components located directly on the controller 1130, or may include components located remotely from the controller 1130 (e.g., foot pedals or similar devices). The controller 1130 can also automatically control the components of the system 100 without requiring input from a user. In one embodiment, a user can program software into the controller 1130 to enable such automatic control. The controller 1130 can control the operation of mechanical portions of the flow control assembly 125. The controller 1130 may include circuitry or programming that interprets the signals generated by the sensors 1135, 1140 such that the controller 1130 can control the operation of the flow control assembly 125 in response to the signals generated by the sensors.

[0097] The representation of the controller 1130 shown in FIG. 11 is merely exemplary. It should be understood that the appearance and structure of the controller 1130 may be varied as appropriate. In FIG. 11, the controller 1130 is shown as being integrated into a single housing. This allows a user to control the flow control assembly 125 from a single location. It should be noted that any components of the controller 1130 may be separated into separate housings. Additionally, FIG. 11 shows the controller 1130 and the flow control assembly 125 as separate housings. It should be noted that the controller 1130 and the flow control assembly 125 may be integrated into a single housing or may be split into multiple housings or components.

[0098] [Flow Status Indicator] The controller 1130 may include one or more indicators that provide a visual and / or audio signal to the user regarding the status of retrograde blood flow. An audio indication has the advantage that the user may be informed of the status of retrograde blood flow without the user having to visually check the controller 1130. The indicators may include a speaker 1150 and / or a light 1155, or other means for communicating the status of retrograde blood flow to the user. The controller 1130 may be in communication with one or more sensors of the system to control activation of the indicators. Alternatively, activation of the indicators may be directly tied to the user actuating one of the flow control actuators 1165. The indicators are not limited to speakers or lights. The indicators may simply be buttons or switches that visually indicate the status of retrograde blood flow. For example, a button in a particular state (e.g., pressed or down) may visually indicate that retrograde blood flow is in a high state (high flow rate). Alternatively, a switch or dial may be provided that points to a particular labeled flow state, providing a visual indication that retrograde blood flow is in that labeled state.

[0099] The indicator may provide a signal indicative of one or more conditions of retrograde blood flow. In one embodiment, the indicator identifies only two distinct conditions: a "high" flow condition and a "low" flow condition. In another embodiment, the indicator identifies three or more flow rates, including a "high" flow rate, a "medium" flow rate, and a "low" flow rate. The indicator may be configured to identify any distinct condition of retrograde blood flow or may be configured to identify a graduated signal corresponding to a condition of retrograde blood flow. In this regard, the indicator may be a digital or analog meter 1160 that indicates a value of the retrograde blood flow rate, such as ml / min or other units.

[0100] In one embodiment, the indicator is configured to indicate to the user whether the retrograde blood flow rate is in a "high" or "low" flow rate state. For example, the indicator may illuminate in a first manner (e.g., brightness level) and / or emit a first audio signal when the flow rate is high, and then change to a second illumination and / or emit a second audio signal when the flow rate is low. Alternatively, the indicator may illuminate or emit an audio signal only when the flow rate is high or only when the flow rate is low. Since some patients may not be able to tolerate high flow rates or may not be able to tolerate high flow rates for extended periods of time, it may be desirable for the indicator to notify the user when the flow rate is high. This serves as a fail-safe feature.

[0101] In another embodiment, the indicator provides a signal (audio and / or visual) when the flow state changes, such as when the flow rate changes from "high" to "low" and / or vice versa. In another embodiment, the indicator provides a signal when retrograde blood flow is not present, such as when the shunt 120 is blocked or when one of the stopcocks in the shunt 120 is closed.

[0102] [Flow Actuator] The controller 1130 may include one or more actuators that a user may press, toggle, manipulate, or otherwise activate to adjust or monitor the retrograde blood flow rate. For example, the controller 1130 may include a flow control actuator 1165 (e.g., one or more buttons, knobs, dials, switches) that a user may activate to selectively cause the controller to change aspects of the retrograde blood flow. For example, in the illustrated embodiment, the flow control actuator 1165 is a knob that can be turned to various discrete positions that correspond with the controller 1130 to cause the system 100 to achieve a particular retrograde blood flow state. The retrograde blood flow states include, for example, (a) off, (b) low flow, (c) high flow, (d) suction, etc. It should be understood that these states are merely exemplary and that different states or combinations of states may be used. The controller 1130 achieves the various retrograde blood flow states by interacting with one or more components of the system, including sensors, valves, variable flow resistance components, and / or pumps. It should be noted that the controller 1130 also includes circuitry and software for regulating and monitoring the retrograde blood flow rate, thereby eliminating the need for the user to actively operate the controller 1130.

[0103] The off state corresponds to no retrograde blood flow through the shunt 120. When the user sets the flow control actuator 1165 to off, the controller 1130 shuts off valves or closes stopcocks in the shunt 120 to stop retrograde blood flow. A low flow state corresponds to a low retrograde blood flow rate, and a high flow state corresponds to a high retrograde blood flow rate. When the user sets the flow control actuator 1165 to low or high flow, the controller 1130 interacts with components of the flow control assembly (flow control regulator) 125, including the pump 1110, valve 1115, and / or variable flow resistance component 1125, to increase or decrease the flow rate accordingly. Finally, the aspiration state corresponds to opening the circuit to a suction source (e.g., a vacutainer or aspiration unit) when active retrograde blood flow is required.

[0104] The system allows the blood flow to be varied between various states, including active, passive, suction, and off states. The active state corresponds to a system that uses a means to actively drive retrograde blood flow. Such active means include, for example, a pump, a syringe, a vacuum source, and the like. The passive state corresponds to when retrograde blood flow is driven by the perfusion stump pressures of the external carotid artery (ECA) and the internal carotid artery (ICA), and possibly venous pressure. The suction state corresponds to a system that uses a suction source (e.g., a vacutainer or suction unit) to facilitate retrograde blood flow. The off state corresponds to a state in which the retrograde blood flow of the system is zero, for example as a result of closing a stopcock or valve. The low and high flow rates can be either passive or active flow rates. In one embodiment, the specific values ​​of the low and / or high flow rates (e.g., values ​​in ml / min) can be predetermined and / or preprogrammed into the controller, such that the user does not need to actually set or input the values. Rather, the user simply selects "high flow" and / or "low flow" (such as by pressing an actuator such as a button on the controller 1130), and the controller 1130 interacts with one or more components of the flow control assembly 125 such that the flow achieves the predetermined high or low flow value. In another embodiment, the user sets or inputs values ​​for the low and / or high flow into a controller or the like. In another embodiment, the low and / or high flow are not actually set. Rather, external data (e.g., data from the anatomical data sensor 1140, etc.) is used as a basis to affect the flow rate.

[0105] The flow control actuator 1165 may be multiple actuators. For example, one actuator (e.g., a button or switch) switches the state from low flow rate to high flow rate, and another actuator closes the flow loop off, for example, when contrast is directed antegrade into the carotid artery during contrast injection. In one embodiment, the flow control actuator 1165 may include multiple actuators. For example, one actuator may be operated to switch the flow rate from "low" to "high", another actuator may be operated to temporarily stop the flow, and a third actuator (e.g., a stopcock) may be operated to perform aspiration using a syringe. In another example, one actuator is operated to switch to a low flow rate and another actuator is operated to switch to a high flow rate. Alternatively, the flow control actuator 1165 may include multiple actuators to switch the state from low flow rate to high flow rate and additional actuators to fine-tune the flow rate within a range between the high flow rate and low flow rate states. Such additional actuators may be used to fine-tune the flow rate within these states when switching between low flow rate and high flow rate. Thus, it should be appreciated that within each state (i.e., high flow state and low flow state), various flow rates can be set and fine-tuned. A variety of actuators can be used to achieve control of the flow states.

[0106] The controller 1130 or individual components of the controller 1130 may be located in various positions relative to the patient and / or relative to other components of the system 100. For example, the flow control actuator 1165 may be located near a hemostasis valve where an interventional tool is introduced into the patient to facilitate access to the flow control actuator 1165 during introduction of the tool. The location may vary depending on whether a transfemoral approach or a transcarotid approach is used, as shown in FIGS. 1A-1C. The controller 1130 may include a wireless connection and / or an adjustable length wired connection to the rest of the system 100 to allow remote control of the system 100. The controller 1130 may include a wireless connection and / or an adjustable length wired connection to the flow control assembly (flow control regulator) 125 to allow remote control of the flow control assembly (flow control regulator) 125. The controller 1130 may be integrated into the flow control assembly (flow control regulator) 125. Where the controller 1130 is mechanically connected to components of the flow control assembly 125, a tether with mechanical actuation may connect the controller 1130 to one or more components. In one embodiment, the controller 1130 may be located a sufficient distance from the system 100 such that the controller 1130 can be located outside of the radiation field when used for fluoroscopic examination.

[0107] The controller 1130 and any of its components can communicate with other components of the system (e.g., pumps, sensors, shunts, etc.) in various ways. For example, any of a variety of mechanical connections can be used to enable communication between the controller 1130 and the system components. Alternatively, the controller 1130 can communicate electronically or magnetically with the system components. Electromechanical connections can also be used. The controller 1130 can be equipped with control software that enables the controller to implement control functions using the system components. The controller itself can be a mechanical, electrical, or electromechanical device. The controller can be mechanically, pneumatically, or hydraulically actuated (e.g., in the case of solenoid actuation of flow control states), or electromechanically actuated. The controller 1130 can include computer functionality, computer processor functionality, memory functionality, and data storage functionality.

[0108] FIG. 12 illustrates an exemplary embodiment of a variable flow control element (variable flow resistance component 1125). In this embodiment, the flow resistance through the shunt 120 can be altered by providing two or more alternative flow paths to create a low resistance flow path and a high resistance flow path. As shown in FIG. 12A, the flow through the shunt 120 passes through a main lumen 1700 and a secondary lumen 1705. The secondary lumen 1705 is longer and / or has a smaller diameter than the main lumen 1700. Thus, the flow resistance of the secondary lumen 1705 is greater than that of the main lumen 1700. By passing blood through both the main lumen 1700 and the secondary lumen 1705, flow resistance is minimized. Due to the pressure drop that occurs in the main lumen 1700 across the inlet and outlet of the secondary lumen 1705, blood can flow through both the main lumen 1700 and the secondary lumen 1705. This has the advantage of preventing blood stagnation. As shown in FIG. 12B, by blocking flow through the main lumen 1700 of the shunt 120, flow is diverted entirely to the secondary lumen 1705, resulting in increased flow resistance and reduced blood flow rate. It is understood that additional flow lumens may be provided in parallel to allow for three, four, or more separate flow resistances. The shunt 120 may be provided with a valve 1710 that controls flow to the main lumen 1700 and the secondary lumen 1705. The position of the valve may be controlled by an actuator (e.g., a button, switch, etc.) on the housing of the flow control assembly 125. The embodiment of FIG. 12A and FIG. 12B has the advantage of maintaining a precise lumen size even at the lowest flow setting. The size of the secondary lumen may be configured to prevent the formation of thrombus even under the lowest flow or prolonged flow conditions. In one embodiment, the inner diameter of the secondary lumen 1705 is 0.063 inches or greater.

[0109] 13A-13C show an embodiment of a flow control assembly 125 in which many of the shunt components and functions are contained or housed within a single housing 1300. This configuration simplifies and reduces the space required for the flow control assembly 125 and the shunt 120. As shown in FIG. 13A, the housing 1300 houses a variable flow control element (variable flow resistance component 1125) of the style illustrated in FIG. 12. An actuator 1330 moves a valve 1710 back and forth so that the flow resistance in the shunt can be transitioned between low and high resistance states. In FIG. 13A, the valve is in an open position and the shunt is in a low resistance (high flow) state. In FIG. 13B, the valve 1710 is in a closed position and the shunt is in a high resistance (low flow) state. A second actuator 1340 moves a second valve 1720 back and forth so that the shunt line (shunt 120) can be opened and closed. In Figures 13A and 13B, the valve 1720 is in an open position, allowing flow through the shunt 120. In Figure 13C, the valve 1720 is in a closed position, completely stopping flow through the shunt 120. The housing 1300 also houses a filter 1145 and a one-way check valve (flow control valve 1115). In one embodiment, the housing may be opened after the procedure and the filter 1145 may be removed. An advantage of this embodiment is that the filter may be washed and inspected after the procedure, allowing the physician to have direct visual evidence of the embolic debris captured by the system during the procedure.

[0110] In a preferred embodiment, the connectors connecting the elements of the retrograde blood flow system are large bore quick connect style connectors. For example, as shown in FIG. 9B, a male large bore hub 680 on a Y-adapter 660 of the arterial sheath (arterial access device 110) connects to a female corresponding hub 1320 on the arterial side of the shunt 120, as shown in FIG. 13. Similarly, as shown in FIG. 10C, a male large bore connector 1310 on the venous side of the shunt 120 connects to a female corresponding connector 1310 on the flow path of the venous sheath (venous return device 115). The connected retrograde blood flow system 100 is shown in FIG. IE. This preferred embodiment reduces flow resistance through the shunt, allowing for higher flow rates, and prevents accidentally connecting the shunt backwards (check valve in the wrong orientation). In another embodiment, the connections are standard female and male Luer connectors, or other style tubing connectors.

[0111] [Sensor] As previously mentioned, the flow control assembly 125 may include or be in communication with one or more sensors in communication with the system 100 and / or with the patient's anatomy. Each sensor may be configured to respond to a physical stimulus (e.g., heat, light, sound, pressure, magnetism, motion, etc.) and transmit a resulting signal (output signal) for measurement, display, or operation of the controller 1130. In one embodiment, the flow sensor 1135 interacts with the shunt 120 to sense a characteristic of the flow (e.g., blood flow rate or volumetric flow rate) through the shunt 120. The flow sensor 1135 may be directly connected to a display that directly displays the volumetric flow or flow rate value. Alternatively, the flow sensor 1135 may transmit data to the controller 1130 for display of the volumetric flow or flow rate.

[0112] The flow sensor 1135 may be of various types. The flow sensor 1135 may be a mechanical device, such as a paddle wheel, a flapper valve, a rolling ball, or any mechanical component that responds to flow through the shunt 120. The movement of the mechanical device in response to flow through the shunt 120 may serve as a visual indication of the fluid flow and may be calibrated to a scale as a visual indication of the fluid flow rate. The mechanical device may be coupled to an electrical component. For example, a paddle wheel may be positioned within the shunt 120 such that the flow of fluid rotates the paddle wheel, and the greater the fluid flow rate, the faster the paddle wheel rotates. The paddle wheel may be magnetically coupled to a Hall effect sensor such that the speed of rotation can be detected, which may indicate the flow rate of the fluid through the shunt 120.

[0113] In one embodiment, the flow sensor 1135 is an ultrasonic, electromagnetic, or electro-optical flow meter that can measure blood flow without contacting the blood through the walls of the shunt 120. The ultrasonic or electromagnetic flow meter can be configured so that it does not need to contact the lumen of the shunt 120. In one embodiment, the flow sensor 1135 at least partially comprises a Doppler flow meter, such as a transonic flow meter, that measures the flow of fluid through the shunt 120. In another embodiment, the flow sensor 1135 measures a pressure difference along the flow path so that the flow rate can be measured. It should be noted that a wide variety of sensor types can be used, including ultrasonic flow meters and transducers. Additionally, the system may include multiple sensors.

[0114] The system 100 is not limited to the use of a flow sensor 1135 disposed within the shunt 120 or a sensor that interacts with the venous return device 115 or the arterial access device 110. For example, the anatomical data sensor 1140 may communicate with or otherwise interact with the patient's anatomy (e.g., the patient's neurological anatomy, etc.). In this manner, the anatomical data sensor 1140 may sense a measurable anatomical characteristic that is directly or indirectly related to the rate of retrograde blood flow from the carotid artery. For example, the anatomical data sensor 1140 may measure blood flow conditions in the brain (e.g., flow velocity in the middle cerebral artery) and communicate the conditions to the display and / or controller 1130 to adjust the rate of retrograde blood flow based on predetermined criteria. In one embodiment, the anatomical data sensor 1140 comprises a transcranial Doppler ultrasound (TCD), which is an ultrasound test that uses reflected sound waves to assess blood flow in the brain. Use of the TCD generates a TCD signal that can be communicated to the controller 1130, which can control the rate of retrograde blood flow to achieve or maintain a desired TCD profile. The anatomical data sensor 1140 can be based on any physiological measurement, including retrograde blood flow rate, blood flow through the middle cerebral artery, a TCD signal of embolic particles, or other neuromonitoring signals.

[0115] In one embodiment, the system 100 includes a closed-loop control system. In a closed-loop control system, one or more sensors (e.g., flow sensor 1135 or anatomical data sensor 1140, etc.) sense or monitor a predetermined characteristic of the system 100 or anatomy (e.g., retrograde blood flow rate and / or neuromonitoring signals, etc.). The sensors transmit relevant data to the controller 1130, which continually adjusts the system characteristics as needed to maintain a desired retrograde blood flow rate. The sensors communicate feedback to the controller 1130 on how the system 100 should operate, which the controller 1130 converts to actuate components of the flow control assembly 125 to dynamically correct for disturbances in the retrograde blood flow rate. For example, the controller 1130 may include software that causes the controller 1130 to signal components of the flow control assembly 125 to adjust the flow rate so that the flow rate remains constant across different patient blood pressures. In this embodiment, system 100 need not rely on a user to determine the timing, duration, and / or value at which to set the retrograde blood flow rate to a "high" or "low" state. Rather, software within controller 1130 may control such elements. In a closed loop system, controller 1130 may control components of flow control assembly 125 to establish a level or state of retrograde blood flow (an analog level or a discrete state such as "high," "low," "baseline," "medium," etc.) based on the retrograde blood flow rate sensed by sensor 1135.

[0116] In one embodiment, the anatomical data sensor 1140 (measuring a physiological measurement of the patient) communicates a signal to the controller 1130, which adjusts the flow rate based on the signal. For example, the physiological measurement may be based on blood flow velocity through the middle cerebral artery (MCA), a TCD signal, or other cerebrovascular signal. In the case of a TCD signal, transcranial Doppler ultrasonography (TCD) may be used to monitor changes in cerebral blood flow and detect microemboli. The controller 1130 may adjust the flow rate to maintain the TCD signal within a desired profile. For example, the TCD signal may indicate the presence of a microembolus (a "TCD hit") and the controller 1130 may adjust the rate of retrograde blood flow to maintain the TCD hit below a hit threshold (see, for example, Ribo et al., Stroke 2006, Volume 37, 2846-2849, "Transcranial Doppler Monitoring of Transcervical Carotid Stenting with Flow Reversal Protection: A Novel Carotid Revascularization Technique" and Shekel et al., Acta Neurochir, 2007, 149:681-689, "Experience of 500 Cases of Neurophysiological Monitoring in Carotid Endarterectomy," the entire contents of which are incorporated herein by reference).

[0117] In the case of middle cerebral artery (MCA) flow, the controller 1130 may set the retrograde blood flow rate to the "maximum" flow rate that the patient can tolerate, as assessed by perfusion to the brain. In this way, the controller 1130 may control the retrograde blood flow rate to optimize the level of protection for the patient without relying on user intervention. In another embodiment, feedback is provided based on the state of the devices in the system 100 or the interventional tools being used. For example, a sensor may notify the controller 1130 when the system 100 is in a high-risk state, such as when an interventional catheter is placed in the sheath 605. The controller 1130 adjusts the flow rate to correct for such a condition.

[0118] The controller 1130 may be used to selectively augment retrograde blood flow in various ways. For example, it has been recognized that a higher retrograde blood flow rate results in a further reduction in blood flow to the brain, particularly the ipsilateral MCA, which may not be fully compensated for by collateral circulation from the Circle of Willis. Thus, a prolonged high retrograde blood flow rate may result in a state in which the patient's brain does not receive sufficient blood flow, leading to the patient's intolerance, which manifests as neurological symptoms. Studies have shown that when the MCA blood flow velocity falls below 10 cm / sec, the patient is at risk for neurological blood insufficiency, thus becoming a threshold. Other markers for monitoring adequate perfusion to the brain include EEG signals. However, a high flow rate may be tolerated for a short period of time (up to about 15 seconds to 1 minute) before flow in the middle cerebral artery (MCA) is completely stopped.

[0119] In this manner, the controller 1130 may optimize the capture of embolic debris by automatically increasing retrograde blood flow only during limited periods of time that correspond to periods of increased risk of emboli generation during the procedure. These periods of increased risk include periods during which the interventional device (e.g., a balloon catheter or stent delivery device, etc., before and / or after stent expansion) passes through the plaque P. Another period is during interventional procedures such as stent deployment and inflation and deflation of the balloon catheter before or after expansion. A third period is during contrast injection for angiographic imaging of the treatment site. During periods of low risk, the controller may return the retrograde blood flow rate to a low baseline level. This low level may correspond to low ICA retrograde blood flow rate or negligible antegrade flow rate in patients with high ECA or ICA perfusion pressure ratios.

[0120] In a flow regulation system where the user manually sets the flow state, there is a risk that the user will not pay attention to the state of retrograde blood flow ("high" or "low") and will inadvertently maintain the circuit at a high flow rate. This may result in adverse reactions in the patient. In one embodiment, as a safety mechanism, the default flow rate is a low flow rate. This serves as a fail-safe measure for patients who cannot tolerate high flow rates. In this regard, the controller 1130 may bias the default flow rate to return the system to a low flow rate after a predetermined high flow period has elapsed. Such biasing to a low flow rate may be achieved by electronics, software, mechanical components, or a combination of mechanical and electronic components. In one embodiment, the flow control actuator 1165 of the controller 1130 and / or the valve 1115 and / or pump 1110 of the flow control assembly (flow control regulator) 125 are spring loaded toward a state that provides a low flow rate. The controller 1130 is configured to allow the user to override the controller 1130 and manually return the system to a low flow rate state if necessary.

[0121] As another safety feature, the controller 1130 includes a timer 1170 (FIG. 11) that records the time for how long the flow rate was at the high flow rate. The controller 1130 may be programmed to automatically return the system 100 to the low flow rate after a predetermined period of high flow rate (e.g., 15, 30, or 60 seconds or more). After the controller returns to the low flow rate, the user may initiate another predetermined high flow rate period, if desired. Additionally, the user may override the controller 1130 to transition the system 100 to a low flow rate (or high flow rate) if desired.

[0122] In an exemplary procedure, the level of retrograde blood flow is initially set to a low rate, then switched to a high rate for a period of time at a critical stage of the procedure, optimizing the capture of embolic debris so that patient tolerance issues do not arise. Alternatively, the flow rate is initially set high and the patient's tolerance to that level is ascertained before proceeding with the remainder of the procedure. If the patient shows signs of intolerance, the retrograde blood flow rate is lowered. The patient's tolerance is determined automatically by the controller based on feedback from the anatomical data sensor 1140, or by the user based on patient observations. Adjustments to the retrograde blood flow rate may be performed automatically by the controller or manually by the user. Alternatively, the user may monitor blood flow velocity through the middle cerebral artery (MCA), for example, using transcranial Doppler ultrasonography (TCD), and set a maximum level of retrograde blood flow that maintains the MCA blood flow velocity above a threshold level. In this situation, the entire procedure may be performed without changing the blood flow conditions. If the MCA blood flow velocity changes during the course of the procedure or the patient shows neurological symptoms, adjustments may be made as necessary.

[0123] [Kit and package configuration examples] In an exemplary embodiment of the retrograde blood flow system 100, all components of the retrograde blood flow system are packaged together in a single sterile package. The sterile package includes an arterial sheath, an arterial sheath expander, a venous sheath, a venous sheath expander, a shunt / controller, and one or more sheath guidewires. In one configuration, the components of the retrograde blood flow system are mounted on a flat card (e.g., a cardboard or polymer card, etc.) with one or more openings or cutouts sized and shaped to receive and secure the components. In another configuration, the card is configured to open and close like a book or clamshell to reduce the profile of the package. In this embodiment, the card may have a cutout to reveal at least a portion of the product when the card is in a closed configuration. FIG. 15A shows the kit mounted on a book card 1510 in an open configuration. FIG. 15B shows the kit with the book card 1510 in a closed configuration. The cutout 1520 allows visualization of at least one packaged device, such as the flow control housing 1300, even when the card is in a closed configuration. FIG. 15C shows the kit and book card inserted into further package components, including a sterilization pouch 1530 and a shelf carton 1540. In this embodiment, the shelf carton 1540 also includes a cutout 1550 that aligns with the cutout 1520 of the book card 1510, allowing visualization of at least a portion of the product from outside the closed shelf carton, as shown in FIG. 15D. A nylon or other transparent film material may be applied to the cutout 1550 of the shelf carton 1540 to protect the sterilization pouch 1530 from dirt and damage.

[0124] In one embodiment, the package card, either in a flat or book version, may be printed with component names, connection instructions, and / or setup instructions to aid in the setup and use of the device.

[0125] In another embodiment, the arterial access device, the venous return device, and the shunt with flow controller may be packaged in three separate sterile packages, for example, the arterial access device including the arterial access sheath, sheath expander, and sheath guidewire may be packaged in one sterile package, the venous return device including the venous return sheath, venous sheath expander, and sheath guidewire may be packaged in a second sterile package, and the shunt with flow controller may be packaged in a third sterile package.

[0126] [Embodiment of the stent] Various embodiments of stents configured for use in transcarotid and / or transfemoral procedures (e.g., deployed in various vasculature systems (e.g., carotid vasculature)) are described below. Although examples are provided herein for the use of stents in transcarotid procedures for deployment in the carotid vasculature, stents according to embodiments described herein may also be used for other applications (e.g., transfemoral procedures) without departing from the scope of the present disclosure. The stents described herein may be configured to treat vascular blockages, such as those caused by atherosclerosis, and improve blood flow along various vasculature systems. For example, the stents may be self-expanding or may be expanded using one of a variety of stent expansion devices (e.g., an expandable balloon). The stents may be configured to be capable of transitioning between a contracted configuration (a collapsed configuration) and an expanded configuration (an expanded configuration). For example, the stent (i.e., the elongated tubular body of the stent) may form a contracted configuration having a first diameter such that the stent can be inserted and positioned in a vasculature (e.g., the carotid vasculature). Additionally, the stent (i.e., the elongated tubular body of the stent) may form an expanded configuration having a second diameter greater than the first diameter, such as when deployed at a treatment site (e.g., a site of atherosclerosis). The stent is expandable radially outward relative to a longitudinal axis of the stent.

[0127] Stents can be made from one or more of a variety of materials. For example, the stent may be made of a material that allows the stent to self-expand or transition from a contracted to an expanded configuration with or without assistance, such as a shape-memory material (e.g., Nitinol) or a biocompatible material. Stents according to embodiments described herein may be used with any of the access and flow control systems and features described herein. Additionally, balloon catheters may be used before and after stent deployment procedures, such as preparing the treatment site for carotid stent deployment and expanding the stent within the treatment site (e.g., to achieve a desired circumference of the deployed stent).

[0128] 16A-16B illustrate an embodiment of a stent 1600 having an elongated tubular body 1610. Additionally, the stent 1600 may include a plurality of strut rings 1616. The strut rings 1616 are disposed about the longitudinal axis L of the tubular body 1610, i.e., extend circumferentially about the tubular body 1610. Each strut ring 1616 may include a plurality of struts 1615. The plurality of struts 1615 form a zigzag configuration along the length of the strut ring 1616. For example, each strut ring 1616 may include a plurality of struts 1615 that are angled relative to adjacent struts 1615 and are configured to be coupled to adjacent struts 1615 at strut joints 1614. That is, each strut ring 1616 may include a plurality of strut joints 1614. As shown in Figure 16A, in some embodiments, the strut joints 1614 of two adjacent strut rings 1616 may be approximately aligned with one another. The two adjacent strut rings 1616 may be circumferentially offset, for example, by one strut joint 1614. Such a circumferential offset may result in a mirror image of the two adjacent strut rings 1616, as shown in Figure 16A. The strut joints 1614 may be flexible to allow adjacent struts 1615 to pivot toward and away from one another. This may facilitate the formation of the contracted and expanded configurations of the stent 1600.

[0129] Each strut ring 1616 may be connected to and spaced apart from adjacent strut rings 1616 by one or more bridges 1620. As shown in FIG. 16A, each bridge 1620 may comprise a nonlinear (e.g., zigzag) shaped extension of material that extends between strut joints 1614 of adjacent strut rings 1616. The bridges 1620 may have different lengths and / or nonlinear shapes, which may affect the flexibility and ability of the stent 1600 to conform to the vasculature. For example, the longer the length of material forming the nonlinear shape of the bridge 1620, the easier the bridge 1620 will bend (e.g., less force is required to deform and / or stretch). This may allow adjacent strut rings 1616 to move (e.g., expand, contract, pivot) more easily relative to one another (e.g., less force is required to move adjacent strut rings 1616 relative to one another). This facilitated movement of adjacent strut rings 1616 provides a more flexible portion of the stent 1600. Additionally, the more flexible portion of the stent 1600 may be more likely to effectively conform to the surrounding vasculature. The various lengths and shapes of the bridges 1620 may also help to effectively anchor the stent 1600 at the treatment site.

[0130] As shown in FIG. 16A , each of the plurality of strut rings 1616 of the tubular body 1610 may be connected to an adjacent strut ring 1616 via one or more bridges 1620. The struts 1615 and bridges 1620 may form and / or define a plurality of cells. The plurality of cells, each having a cell area 1622, may be formed around the periphery of the stent 1600 and along the length of the stent 1600. Further, as shown in FIG. 16A , the plurality of cells may include at least one open cell 1625, at least one closed cell 1630, or a combination of open and closed cells 1625 and 1630. Each closed cell 1630 may include a pair of bridges 1620 connecting an adjacent pair of opposing strut joints 1614. In contrast, an open cell 1625 may include a pair of strut joints 1614 of an adjacent pair of opposing strut joints 1614 that are not connected by a bridge 1620.

[0131] The stent 1600 may be configured to be insertable and deployable along a portion of the carotid vasculature. Once deployed and expanded, the stent 1600 may provide improved functionality over at least some currently available stents, such as improved flexibility along the length of the stent, improved conformance to adjacent anatomical structures, sufficient attachment to adjacent anatomical structures, and / or reduced vascular tortuosity. For example, such improvements may be achieved by a first pattern change 1612 formed by a plurality of strut rings 1616 and a plurality of bridges 1620 along the length of the elongated tubular body 1610 of the stent 1600.

[0132] For example, the first pattern variation 1612 may include a change in bridge length 1621 of the bridges 1620 disposed along the length (longitudinal axis) of the tubular body 1610 of the stent 1600. Additionally, in some embodiments, the first pattern variation 1612 may include a change in strut length 1617 of the struts 1615 disposed along the length (longitudinal axis L) of the stent 1600. For example, the bridge length 1621 and / or strut length 1617 disposed along the tubular body 1610 of the stent 1600 may be defined and / or determined based on a polynomial function (e.g., a fourth order polynomial). Varying the bridge length 1621 and / or strut length 1617 defined by the polynomial function allows the stent 1600 to have a flexible shape along the length of the stent 1600. This may improve the ability of the stent to conform to the vascular anatomy, improve adhesion to the vessel wall, and reduce the likelihood of vessel kinking.

[0133] As shown in FIGS. 16A and 16B, the stent 1600 may include a first pattern change 1612 including a proximal section 1640, a middle section 1642, and a distal section 1644. As shown in FIGS. 16A and 16B, the proximal section 1640 may include a plurality of open cells 1625 arranged in two circumferential rows. The open cells 1625 of the proximal section 1640 are adjacently disposed along the proximal end 1618 of the stent 1600. As shown in FIGS. 16A and 16B, the distal section 1644 may include a plurality of open cells 1625 arranged in two circumferential rows. The open cells 1625 of the distal section 1644 are adjacently disposed along the distal end 1619 of the stent 1600. As shown in FIG. 16A, the middle section 1642 between the proximal section 1640 and the distal section 1644 may include a plurality of closed cells 1630. As described in more detail below, the first pattern variation 1612 can include a variation in bridge length 1621 along the length of the stent 1600. This can enable the stent 1600 to achieve the improvements disclosed herein as compared to at least some currently available stents.

[0134] 16B, the bridge length 1621 of the bridges 1620 may increase along the length of the stent 1600 (e.g., along the proximal section 1640 and the mid-section 1642). Additionally, the bridge length 1621 along the proximal section 1640 and the mid-section 1642 may increase gradually along the distal direction (e.g., the length of the bridges 1620 located closer to the proximal end 1618 may be shorter than the length of the bridges 1620 located closer to the distal end 1619 of the stent 1600). In some embodiments, the distal section 1644 may have the same or similar bridge length and / or may have a shorter bridge length compared to the bridge length 1621 along the mid-section 1642 or the proximal section 1640. The bridge length 1621 along the distal section 1644 may have approximately the same (approximately uniform) length and may be shorter compared to at least some of the more proximal bridges 1620.

[0135] 16C illustrates a graph 1675 showing the increase in bridge length 1621 of bridges 1620 along the length of the stent 1600 (e.g., the proximal section 1640 and the middle section 1642) (e.g., the bridge length gradually increases along the distal direction). For example, as shown in FIG. 16B, the first of the plurality of bridges 1620a adjacent the proximal end 1618 of the stent 1600 may have the shortest length compared to the other bridges 1620b-1620i. Additionally, the length of the bridges 1620 may gradually increase along the distal direction, e.g., the ninth of the plurality of bridges 1620i proximal to the distal end 1619 of the stent 1600 may have the longest length. As shown in Figures 16B and 16C, in some embodiments, the bridges 1620 extending between the two most distal strut rings 1616 (e.g., the bridges 1620j along the distal section 1644) may have the same or approximately the same length and may be shorter compared to at least some of the more proximal bridges (e.g., the ninth bridges 1620i).

[0136] The stent 1600 may have a variety of lengths, such as from about 20 millimeters (mm) to about 50 mm (e.g., 30 mm, 40 mm). Additionally, the stent 1600 may include a variety of pattern variations having a variety of bridge lengths 1621 that define or are defined by a polynomial function (e.g., a fourth order polynomial). As shown in FIG. 16C, the variation in bridge length 1621 of a first pattern variation 1612 of the stent 1600 may be approximately defined by a polynomial function (e.g., a fourth order polynomial) 1630. For example, as shown in graph 1675 of FIG. 16C, a first polynomial function 1630a may define an embodiment of the stent 1600 that is about 50 mm long, and a second polynomial function 1630b may define an embodiment of the stent 1600 that is about 30 mm long. For example, the first polynomial function 1630a and the second polynomial function 1630b may both be fourth order polynomials, but differ in that they are based on different stent lengths. In some embodiments, the bridge length 1621 may be tapered along the distal portion of the length (e.g., may be tapered along at least a portion of the distal section 1644 compared to at least the middle section 1642) to allow the distal end of the stent 1600 to maintain an appropriate radial force, e.g., to expand sufficiently to fit against the vessel wall.

[0137] In some embodiments, the lengths of the struts 1615 may be the same (uniform) or approximately the same (approximately uniform). In some embodiments, the lengths of the struts 1615 may vary. The stent 1600 may include any number of multiple strut rings 1616 and bridges 1620 and is not limited to the number of struts 1615, strut rings 1616, and / or bridges 1620 shown or disclosed herein.

[0138] For example, the first pattern change 1612 may include struts 1615 having substantially the same strut length 1617 along the entire length of the stent 1600, which may provide a consistent radial force along the entire length of the stent 1600, such as against a carotid artery. Additionally, the first pattern change 1612 may have a bridge 1620 length that increases distally along the length of the stent 1600 (e.g., along the mid-section 1642), which may provide the stent 1600 with greater flexibility distally, at least along the mid-section 1642. This may allow the stent 1600 to maintain a desired conformability at both the proximal 1618 and distal 1619 ends of the stent. For example, a distal flexibility bias along at least the mid-section 1642 allows the distal end 1619 of the stent 1600 to be relatively flexible and adaptable to the more tortuous anatomy of the internal carotid artery (ICA) bifurcation, while the proximal end 1618 of the stent 1600 can be expanded and anchored within the common carotid artery (CCA).

[0139] 17A-17B illustrate another embodiment of a stent 1600 having an elongated tubular body 1610 for deployment in a portion of the carotid vasculature to improve blood flow along the portion. As shown in FIGS. 17A and 17B, the stent 1600 can include a second pattern change 1712 including a proximal section 1740, a middle section 1742, and a distal section 1744. As shown in FIGS. 17A and 17B, the proximal section 1740 can include a plurality of open cells 1625 arranged in two circumferential rows. The open cells 1625 of the proximal section 1740 are adjacently disposed along a proximal end 1618 of the stent 1600. As shown in FIGS. 17A and 17B, the distal section 1744 can include a plurality of open cells 1625 arranged in two circumferential rows. The open cells 1625 of the distal section 1744 are adjacently disposed along the distal end 1619 of the stent 1600. The proximal section 1740 and the distal section 1744 may be free of closed cells 1630. As shown in FIG. 17A, the middle section 1742 located between the proximal section 1740 and the distal section 1744 may include a plurality of closed cells 1630. The middle section 1748 may be free of open cells 1625. As described in more detail below, the second pattern variation 1712 may include a variation in bridge length 1621 along the length of the stent 1600. This may allow the stent 1600 to achieve the improvements disclosed herein as compared to at least some currently available stents. Additionally, the stent 1600 shown in FIG. 17A may include a variation in the length of the struts along the distal section 1744.

[0140] 17B, ​​for example, the bridge lengths 1621 of the bridges 1620 may increase progressively along the length of the stent 1600 (e.g., along the proximal section 1740 and the mid-section 1742). Additionally, the bridge lengths 1621 may increase progressively distally along the length of the stent 1600 (e.g., the bridges 1620 located closer to the proximal end 1618 of the stent 1600 may be shorter compared to the bridges 1620 located closer to the distal end 1619 of the stent 1600). In some embodiments, the distal section 1744 may have the same or similar bridge lengths and / or may have a shorter length compared to the bridge lengths 1621 along the mid-section 1742 or the proximal section 1740. As shown in FIG. 17B, the bridge lengths 1621 along the distal section 1744 may have approximately the same (approximately uniform) length and may have a shorter length compared to at least some of the more proximal bridges 1620.

[0141] FIG. 17C illustrates a graph 1775 showing an increase in bridge length 1621 of bridges 1620 along the length of the stent 1600 (e.g., along the proximal section 1740 and at least a majority of the middle section 1742). For example, as shown in FIG. 17B, the first of the plurality of bridges 1620a adjacent the proximal end 1618 of the stent 1600 may have a shortest length compared to the other bridges 1620b-1620i. Further, the length of the bridges 1620 may increase gradually in a distal direction, for example, the ninth of the plurality of bridges 1620i proximal to the distal end 1619 of the stent 1600 may have the longest length. As shown in FIGS. 17B and 17C, in some embodiments, the length of the plurality of bridges 1620 extending between the two most distal strut rings 1616 (e.g., the plurality of bridges 1620j, 1620k along the distal section 1744) may decrease gradually in a distal direction.

[0142] 17C, the variation in bridge length 1621 in the second pattern variation 1712 may be approximately defined by a polynomial function 1730 (e.g., a fourth order polynomial) (e.g., a first polynomial function 1730a defining an embodiment of the stent 1600 having a length of about 50 mm, and a second polynomial function 1730b defining an embodiment of the stent 1600 having a length of about 30 mm, as shown in graph 1775 of FIG. 17C). As discussed above, the stent 1600 may have a variety of lengths (e.g., about 20 mm, 40 mm) without departing from the scope of the present disclosure. In addition to the variation in bridge length 1621 along the stent 1600, in some embodiments, the length of the struts 1615 may also vary along the length and / or circumference of the stent 1600. For example, the struts 1615 disposed along the distal section 1744 may have a different length as compared to the struts 1615 along the proximal section 1740 and the middle section 1742. For example, the length of the struts 1615 along the proximal section 1740 and the middle section 1742 may be about 0.054 inches (e.g., about 0.0538 inches). Additionally, the length of the last (most distal) two struts 1615 along the distal section 1744 (open cell section) may range from about 0.057 inches to about 0.06 inches, such as about 0.0568 inches (the most distal strut 1615) and 0.0594 inches (the penultimate strut 1615).

[0143] In some embodiments, the second pattern change 1712 may include struts 1615 with reduced or increased strut length 1617 along either the proximal or distal end of the stent 1600. For example, a longer strut length 1617 reduces the radial force of the stent 1600 and increases the flexibility of the associated bridges 1620 relative to the strut rings 1616, thereby improving the flexibility of the stent 1600. For example, the second pattern change 1712 may include an increase in strut length 1617 in a distal direction along the stent 1600. This allows for a distal flexibility bias while still allowing the stent 1600 to maintain a desired form conformability in the anatomy both proximal and distal to the treatment site.

[0144] 18A-18B illustrate another embodiment of a stent 1600 having an elongated tubular body 1610 for deployment in a portion of the carotid vasculature to improve blood flow along the portion. As shown in FIGS. 18A and 18B, the stent 1600 can include a third pattern change 1812 including a proximal section 1840, a middle section 1842, and a distal section 1844. As shown in FIGS. 18A and 18B, the proximal section 1840 can include a plurality of open cells 1625 arranged in two circumferential rows. The open cells 1625 of the proximal section 1840 are adjacently disposed along a proximal end 1618 of the stent 1600. As shown in FIGS. 18A and 18B, the distal section 1844 can include a plurality of open cells 1625 arranged in two circumferential rows. The open cells 1625 of the distal section 1844 are adjacently disposed along the distal end 1619 of the stent 1600. The proximal section 1840 and the distal section 1844 may be free of closed cells 1630. As shown in FIG. 18A, the middle section 1842 located between the proximal section 1840 and the distal section 1844 may include a plurality of closed cells 1630. The middle section 1848 may be free of open cells 1625. As described in more detail below, the third pattern variation 1812 may include a variation in bridge length 1621 along the length of the stent 1600. This may enable the stent 1600 to achieve the improvements disclosed above as compared to at least some currently available stents. For example, as shown in FIG. 18B, the bridge lengths 1621 of the bridges 1620 may decrease approximately symmetrically from the midline (centerline perpendicular to the axis) M of the stent 1600 toward both the proximal and distal ends of the stent 1600.

[0145] 18C shows a graph 1875 illustrating a symmetric decrease in bridge length 1621 from the midline M of the stent 1600. For example, as shown in FIG. 18B, the first of the plurality of bridges 1620a adjacent the proximal and distal ends 1618, 1619 of the stent 1600 may have the shortest bridge length compared to the other plurality of bridges 1620b-1620f. This symmetric stent configuration may concentrate flexibility along the center of the stent 1600, maximizing conformability to the anatomy regardless of stent orientation.

[0146] As shown in FIG. 18C, the change in bridge length 1621 in the third pattern change 1812 may be approximately defined by a polynomial function 1830 (e.g., a fourth order polynomial) (e.g., a first polynomial function 1830a defining an embodiment of the stent 1600 having a length of about 50 mm, and a third polynomial function 1830b defining an embodiment of the stent 1600 having a length of about 30 mm, as shown in graph 1875 of FIG. 18C). As mentioned above, the stent 1600 may have a variety of lengths (e.g., about 20 mm, about 40 mm) without departing from the scope of the present disclosure. In addition to the change in bridge length 1621 along the stent 1600, in some embodiments, the strut length may also vary or remain the same (constant) over the length of the stent 1600.

[0147] In some embodiments, the bridges 1620 may have bridge lengths 1621 that extend linearly (straight) or nonlinearly (non-straight) between the strut joints 1614, such as the nonlinear (e.g., zigzag) bridges 1620 shown in FIG. 18A. For example, the bridges 1620 may extend nonlinearly (e.g., zigzag) between the ends of adjacent struts 1615. The bridges 1620 may have bridge lengths 1621 that are longer than the linear distance between adjacent struts 1615, i.e., adjacent strut joints 1614, at least in the portions that form the nonlinear or zigzag shape. For example, nonlinear bridge formation may help allow the stent 1600 to bend and conform to the surrounding vessel. Other nonlinear bridge 1620 formations are within the scope of the present disclosure.

[0148] In some embodiments, the strut length 1617 of an embodiment of a strut 1615 can be in the range of about 0.04 mm to about 0.07 mm. In some embodiments, the bridge length 1621 of an embodiment of a bridge 1620 can be in the range of about 0.5 mm to about 1.4 mm. Other dimensions of the struts 1615 and bridges 1620 are within the scope of this disclosure.

[0149] [Example Usage] Next, with reference to Figures 14A-14B, flow through the carotid bifurcation at various stages of the method of the present invention will be described. First, as shown in Figure 14A, the sheath 605 of the arterial access device 110 is introduced into the common carotid artery (CCA). As previously described, entry into the common carotid artery (CCA) can be by either direct surgical incision or percutaneous access. After the sheath 605 of the arterial access device 110 is introduced into the common carotid artery (CCA), blood flow continues in the antegrade direction AG, with flow from the common carotid artery entering both the internal carotid artery (ICA) and the external carotid artery (ECA), as shown in Figure 14A.

[0150] Next, a venous return device 115 is inserted into a venous return site, such as the internal jugular vein (IJV) (not shown in FIGS. 14A-14G) or the femoral vein. A shunt 120 is used to connect to the flow path 615 of the arterial access device 110 and the flow path 915 of the venous return device 115, respectively (see FIG. 1A). In this manner, the shunt 120 provides a pathway for retrograde blood flow from the arterial access device 110 to the venous return device 115. In another embodiment, as shown in FIG. 1C, the shunt 120 is connected to an external container 130 instead of the venous return device 115.

[0151] Once all components of the system are in place and connected, blood flow through the common carotid artery (CCA) is stopped, typically by occluding the CCA using a tourniquet 2105 or other external vascular occlusion device. In another embodiment, an occlusion element 129 is placed at the distal end of the arterial access device 110. Alternatively, the occlusion element 129 is introduced into a second arterial occlusion device 112 separate from the sheath 605 of the arterial access device 110, as shown in FIG. 2B. The external carotid artery (ECA) may be occluded by a separate occlusion element on the same device (arterial access device 110) or on a separate occlusion device.

[0152] At that point, retrograde blood flow RG begins from the external carotid artery (ECA) and the internal carotid artery (ICA), passing through the sheath 605, the flow passage 615, the shunt 120, and into the venous return device 115 via the flow passage 915. The flow control assembly 125 controls the retrograde blood flow as described above. Figure 14B illustrates the occurrence of retrograde blood flow RG.

[0153] 14C-14D, the placement and use of a balloon catheter 1950 to perform carotid angioplasty and the deployment of an embodiment of a stent 1600 will now be described. The balloon catheter 1950 may be used to perform carotid angioplasty at a treatment site (e.g., an area where blood flow is restricted by plaque and where an embodiment of a stent 1600 may be deployed) while retrograde blood flow is maintained. Prior to introduction of the balloon catheter 1950, a guidewire may be advanced through the arterial access device 110 and along the common carotid artery (CCA) (including the treatment site where carotid angioplasty will be performed). The distal end of the guidewire may be threaded into the balloon catheter 1950 (e.g., along the guidewire lumen 1750). For example, the guidewire may be threaded along the length of the balloon catheter 1950 or along a portion of the length of the balloon catheter 1950, as in the case of a balloon catheter configured for rapid exchange. The balloon catheter 1950 may be advanced along the guidewire to position the balloon 1920 at the distal end of the catheter shaft 1960 in a deflated state along the treatment site.

[0154] For example, the distal end of the balloon catheter 1950 may be inserted into the arterial access device 110 and advanced along the arterial access device 110 until a visual indicator along the balloon catheter 1950 is aligned with a visual alignment marker on the arterial access device 110. This may align the distal end of the soft tip of the balloon catheter 1950 with the distal end and lumen of the sheath 605. This initial positioning procedure may be performed without the use of fluoroscopy.

[0155] After aligning the visual indicator with the visual alignment marker, the balloon 1920 of the balloon catheter 1950 may be guided toward and positioned along the treatment site, as shown in FIG. 14C. Fluoroscopy (e.g., observing the balloon markers under fluoroscopy) may be used as the balloon 1920 is advanced and positioned along the treatment site. After the balloon 1920 is positioned within the treatment site, the balloon 1920 may be inflated (e.g., via fluid provided from a fluid source coupled to the luer 1621 of the balloon catheter 1950). In the inflated state, the outer surface of the balloon 1920 presses against the plaque surrounding the treatment site, thereby performing the carotid angioplasty, as shown in FIG. 14D. After performing the carotid angioplasty, the balloon 1920 may be deflated and the balloon catheter 1950 may be retracted along the guidewire and removed from the arterial access device 110. After being removed from the arterial access device 110, the balloon catheter 1950 is disconnected from the guidewire, leaving the guidewire extending along the treatment site through the arterial access device 110. Prior to removing the arterial access device 110 from the common carotid artery (CCA), the guidewire may be withdrawn from the arterial access device 110.

[0156] 14E-14G, the placement and use of a stent delivery catheter 2110 to deploy an embodiment of a stent 1600 at a treatment site will now be described. While retrograde blood flow is maintained, the stent delivery catheter 2110 is introduced into the sheath 605, as shown in FIG. 14E. The stent delivery catheter 2110 is introduced into the sheath 605 via the hemostasis valve 625 and the proximal extension 610 of the arterial access device 110 (not shown in FIGS. 14A-14G). The stent delivery catheter 2110 is advanced into the internal carotid artery (ICA), and an embodiment of a stent 1600 may be deployed into bifurcation B, as shown in FIG. 14F.

[0157] During periods of high risk of embolism (e.g., during introduction of the stent delivery catheter 2110 and possibly during deployment of the stent 1600), the retrograde blood flow rate may be increased. The retrograde blood flow rate may also be increased during placement and expansion of the balloon catheter (e.g., carotid angioplasty or dilatation before or after stent placement). Under retrograde blood flow, atherectomy may be performed before stent placement.

[0158] Additionally, in some cases, bifurcation B may be flushed by cycling retrograde blood flow between low and high flow rates after stent 1600 has been expanded. The area within the carotid artery where stent 1600 has been placed or otherwise treated may be flushed with blood before normal blood flow is restored.

[0159] As shown in FIG. 14H, while the common carotid artery remains occluded, a post-deployment expansion of the stent 1600 may be performed using a balloon catheter 1950. To perform such post-deployment expansion of the stent 1600, a guidewire may again be threaded through the balloon catheter 1950, thereby advancing the balloon catheter 1950 along the guidewire extending at least between the arterial access device 110 and the treatment site. The balloon catheter 1950 may be advanced and positioned in a manner similar to that described above with respect to performing a carotid angioplasty. However, in the case of post-deployment stent expansion, the balloon 1920 may be advanced to the treatment site with the stent 1600 at least partially expanded. As shown in FIG. 14H, the balloon 1920 may be positioned along the interior channel of the stent 1600, for example, by using fluoroscopy to identify the location of one or more radiopaque components of the balloon catheter 1950 relative to the stent 1600. After the balloon 1920 is properly positioned within the stent 1600, fluid may be pumped into the balloon 1920 to cause the balloon 1920 to become inflated. This may cause the outer surface of the balloon 1920 to press circumferentially against the stent 1600, further expanding the stent in the circumferential direction. This further circumferential expansion of the stent 1600 may improve blood flow through the stent 1600 and further secure the stent 1600 in position along the treatment site. The balloon catheter 1950 may be withdrawn along the guidewire and removed from the common carotid artery (CCA). The guidewire may also be withdrawn from the common carotid artery (CCA).

[0160] Blood flow may be re-established from the common carotid artery to the external carotid artery by temporarily opening the occlusion means present in the artery. The resulting flow may flush the common carotid artery, which may have exhibited slow, turbulent, or stagnant flow during carotid occlusion, into the external carotid artery. Additionally, the same balloon 1920 may be positioned distal to the stent 1600 during both retrograde and forward flow, and then re-established by temporarily releasing the occlusion of the common carotid artery to flush it. This creates a flushing action in the area where the stent was inserted, aiding in the removal of loose or loosely attached embolic debris in that area.

[0161] Optionally, if blood flow continues from the common carotid artery and the internal carotid artery remains occluded, steps may be taken to further treat the carotid artery, such as to loosen emboli from the treatment area. For example, mechanical elements may be used to clean or remove loose or loosely attached plaque or other potential embolic debris within the stent, thrombolysis catheters or other fluid delivery catheters may be used to irrigate the area, or other procedures may be performed. Treatment of in-stent restenosis, for example, with a balloon, atherectomy, or additional stents, may be performed under retrograde blood flow. In another example, an occlusion balloon catheter may include a flow or aspiration lumen or channel that opens proximal to the balloon. Saline, thrombolytic agents, or other fluids may be injected into the treatment area, or blood and debris may be aspirated from the treatment area, without the need for additional devices. Emboli released in this way flow into the external carotid artery, which is generally less sensitive to embolic release than the internal carotid artery. Prophylactic removal of any remaining potential emboli further reduces the risk of emboli being released when blood flow is re-established to the internal carotid artery. Emboli may also be released by retrograde blood flow, in which case they flow through the shunt 120 to the venous system, a filter within the shunt 120, or to an external reservoir 130.

[0162] After the bifurcation has been de-occluded, the occlusion element 129, or alternatively the tourniquet 2105, may be released, allowing antegrade blood flow to be re-established, as shown in Figure 14G. The sheath 605 may then be removed.

[0163] At the end of the procedure or at any point during the procedure, prior to withdrawal of the sheath 605, a self-closing or manual closure element may be placed around the penetration in the wall of the common carotid artery. The self-closing element may be placed at or near the beginning of the procedure, or, optionally, the self-closing element may be placed as the sheath is withdrawn, such as by being released from the distal end of the sheath onto the wall of the common carotid artery. The use of a self-closing element is advantageous because it substantially affects rapid closure of the penetration in the common carotid artery as the sheath is withdrawn. Such rapid closure may reduce or eliminate unexpected bleeding at the end of the procedure or in the event of inadvertent dislodging of the sheath. Additionally, such a self-closing element may reduce the risk of arterial wall dissection occurring during access. Additionally, the self-closing element may be configured to apply a frictional or other retention force to the sheath during the procedure. Such a retention force may be advantageous and reduce the likelihood of inadvertent dislodging of the sheath during the procedure. The self-closing element eliminates the need for vascular surgical closure of the artery with sutures after sheath removal, reduces the need for a large surgical field, and significantly reduces the surgical skill required for the procedure.

[0164] The systems and methods disclosed herein may employ a wide variety of self-closing or manual closure elements, such as mechanical elements including anchor portions and / or automatic closure portions. The anchor portions may consist of hooks, pins, staples, clips, tines, sutures, etc., and are engaged to the exterior surface of the common carotid artery around the penetration to secure the self-closing element when the penetration is fully open. The self-closing element may include a spring-like or other self-closing portion that closes the anchor portion upon removal of the sheath to draw the tissue within the arterial wall closed. No further steps need to be taken to close or seal the penetration, as the closure is sufficient. However, it may be desirable to perform additional sealing of the self-closing element after withdrawal of the sheath, if necessary. For example, the self-closing element and / or the tissue tract in the region of the element may be treated with hemostatic materials, such as bioabsorbable polymers, collagen plugs, adhesives, sealants, clotting factors, or other clotting promoters. Alternatively, the tissue or the self-closing element may be sealed or closed using other procedures, such as electrocautery, suturing, clipping, stapling, etc. Alternatively, the self-closing element may be a self-sealing membrane or gasket material that is attached to the exterior wall of the container with clips, adhesive, bands, or other means. The self-sealing membrane may have an internal opening (e.g., a slit or crosscut) that is normally closed to blood pressure. Any of these self-closing elements may be configured to be placed in an open surgical procedure or to be deployed percutaneously.

[0165] In another embodiment, carotid stenting may be performed after the sheath is placed and the occlusion balloon catheter is deployed in the external carotid artery. A stent with side holes or other features to leave the ostium of the external carotid artery unobstructed may be delivered through the sheath with the guidewire or shaft of the external carotid occlusion balloon received through the side hole. This allows the catheter to be introduced over the guidewire, typically to the internal carotid artery, and the presence of the catheter shaft in the side hole ensures that the side hole is aligned with the ostium of the external carotid artery as the stent is advanced. When the occlusion balloon is positioned in the external carotid artery, the side hole prevents the stent from trapping the shaft of the external carotid occlusion balloon, a drawback of other retrograde blood flow systems. This approach also avoids "tying up" the external carotid artery and, if the stent is covered with graft material, blocking blood flow to the external carotid artery.

[0166] In another embodiment, one or more stents (e.g., one or more stents 1600 of the embodiments shown in Figures 16A, 17A, and 18A) are placed having a shape that substantially conforms to the carotid vasculature, such as the common carotid artery and / or internal carotid artery. For example, the stent 1600 may be formed into a contracted (folded) configuration as it is inserted into the vasculature and positioned along and / or adjacent to the treatment site. Once the desired location is reached, the stent 1600 is formed or allowed to form into an expanded configuration, thereby anchoring the stent 1600 at or near the treatment site. As disclosed herein, embodiments of the stent 1600 have variable bridge 1620 and / or strut 1615 lengths, thereby providing variable flexibility and / or vascular conformance along the length of the stent 1600.

[0167] Due to the wide variation in anatomy between patients, the angle and shape of the bifurcation between the internal and external carotid arteries are widely varied. Thus, a physician may select one or more stents 1600 appropriate for treating a particular anatomy. The patient's anatomy may be determined by angiography or other conventional methods. In some embodiments, the stent may have articulations. Multiple stents each having articulations may be placed first and then articulated to each other in situ to match the angle of the bifurcation between the common and internal carotid arteries. The stent may be placed in the carotid artery to have a sidewall with multiple zones of different densities.

[0168] In another embodiment, the stent 1600 may be positioned where the stent is at least partially covered with graft material at one or both ends. In some embodiments, portions along the midsection of the stent are free of graft material. The midsection of the stent may be deployed adjacent to the entrance of the external carotid artery to allow blood flow from the common carotid artery to the external carotid artery.

[0169] In another embodiment, the stent delivery system may be optimized for transcarotid access by being configured to be shorter and / or stiffer than a system designed for transfemoral access. These modifications improve the ability to precisely rotate and position the stent 1600 during deployment. Additionally, the stent delivery system may be configured to align the stent 1600 to the entrance of the external carotid artery using either an external carotid occlusion balloon or a separate guidewire in the external carotid artery. This is particularly useful for stents with side holes or curved, bent, or angled stents where orientation is important.

[0170] In certain embodiments, the shunt is fixedly connected to the arterial access sheath and the venous return sheath, making the entire replaceable flow assembly and sheath assembly disposable and replaceable as a unit, hi other examples, the flow control assembly may be removably attached to either or both sheaths.

[0171] In one embodiment, the user first determines whether there is a period of increased risk of emboli generation during the procedure. As mentioned above, examples of periods of increased risk include (1) periods when the device is passing through plaque P, (2) during an interventional procedure (e.g., during delivery of a stent, inflation or deflation of a balloon catheter or guidewire), and (3) during injection of contrast agent. The above periods are only examples of periods of increased risk. During such periods, the user sets the flow rate of retrograde blood flow to a high rate for a certain period of time. At the end of the high-risk period or if the patient shows intolerance to the high flow rate, the user returns the flow state to the baseline flow rate. If the system has a timer, the flow state automatically returns to the baseline flow rate after the set time has elapsed. In this case, if the procedure is still in a period of increased embolic risk, the user may reset the flow state to a high flow rate.

[0172] In another embodiment, if the patient exhibits intolerance to the presence of retrograde blood flow, retrograde blood flow is established only during placement of a filter in the internal carotid artery (ICA) distal to plaque P. Retrograde blood flow is stopped while an interventional procedure is performed on plaque P. Retrograde blood flow is then re-established when the filter is removed. In another embodiment, a filter is placed in the internal carotid artery (ICA) distal to plaque P and retrograde blood flow is established while the filter is in place. This embodiment combines the use of a distal filter with retrograde blood flow.

[0173] Although various method and device embodiments are described in detail herein with reference to specific versions, it should be understood that other versions, embodiments, methods of use, and combinations thereof are possible, and therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.

Claims

1. 1. A stent for treating atherosclerosis in the arterial vasculature, comprising: an elongated tubular body configured to be capable of being formed into a contracted configuration and an expanded configuration; The tubular body extends along a longitudinal axis; the tubular body comprises a plurality of strut rings extending circumferentially about the longitudinal axis and a plurality of bridges each configured to connect two adjacent strut rings; The plurality of bridges include: a first set of at least two bridges each having a first length and each configured to connect a first pair of strut rings of the plurality of strut rings, the first set of bridges being positioned at a first location along the longitudinal axis; a second set of at least two bridges each having a second length greater than the first length and each configured to connect a second pair of strut rings of the plurality of strut rings, the second set of bridges positioned at a second location along the longitudinal axis; a third bridge group consisting of at least two bridges each having a third length greater than the second length and each configured to connect a third pair of strut rings of the plurality of strut rings, the third bridge group being disposed at a third position along the longitudinal axis; the first length at the first location, the second length at the second location, and the third length at the third location are defined by a polynomial function based on at least a length of the stent. Stent.

2. The tubular body includes a proximal section having at least one circumferential row of open cells.

2. The stent of claim 1.

3. the proximal and / or distal sections of the tubular body are free of closed cells; The stent of claim 2.

4. the tubular body includes an intermediate section having at least one circumferential row of closed cells; The stent of claim 3.

5. There are no open cells in the intermediate section; 5. The stent of claim 4.

6. The tubular body includes a distal section having at least one circumferential row of open cells.

6. The stent of claim 5.

7. each bridge in the plurality of bridges has a non-linear shape; 7. The stent of claim 6.

8. the first length, the second length, and the third length of the plurality of bridges gradually increase from the proximal section to the mid-section.

7. The stent of claim 6.

9. Each strut ring in the plurality of strut rings includes struts having the same length as each other.

2. The stent of claim 1.

10. each strut ring in the plurality of strut rings includes a plurality of struts having different lengths; the length of the struts increases along the stent; 2. The stent of claim 1.

11. the plurality of bridges increase in length from a midline of the stent; 2. The stent of claim 1.

12. the first location is adjacent a proximal end of the stent and the third location is adjacent a distal end of the stent.

2. The stent of claim 1.

13. 1. A method of operating a stent for treating atherosclerosis in the arterial vasculature, comprising: shrinking the stent to a collapsed configuration for insertion into the arterial vasculature; and expanding the stent to an expanded configuration for at least partially conforming the stent to an arterial vasculature; The stent comprises an elongate tubular body extending along a longitudinal axis; the tubular body comprises a plurality of strut rings extending circumferentially about the longitudinal axis and a plurality of bridges each configured to connect two adjacent strut rings; The plurality of bridges include: a first set of at least two bridges each having a first length and each configured to connect a first pair of strut rings of the plurality of strut rings, the first set of bridges being positioned at a first location along the longitudinal axis; a second set of at least two bridges each having a second length greater than the first length and each configured to connect a second pair of strut rings of the plurality of strut rings, the second set of bridges positioned at a second location along the longitudinal axis; a third bridge group consisting of at least two bridges each having a third length greater than the second length and each configured to connect a third pair of strut rings of the plurality of strut rings, the third bridge group being disposed at a third position along the longitudinal axis; the first length at the first location, the second length at the second location, and the third length at the third location are defined by a polynomial function based on at least a length of the stent. How the stent works.

14. The tubular body includes a proximal section having at least one circumferential row of open cells. A method for operating a stent according to claim 13.

15. the tubular body includes an intermediate section having at least one circumferential row of closed cells; A method for operating a stent according to claim 14.

16. The tubular body includes a distal section having at least one circumferential row of open cells. A method for operating a stent according to claim 15.

17. each bridge in the plurality of bridges has a non-linear shape; A method for operating a stent according to claim 16.

18. the first length, the second length, and the third length of the plurality of bridges gradually increase from the proximal section to the mid-section. A method for operating a stent according to claim 16.

19. each strut ring in the plurality of strut rings includes a plurality of struts having different lengths; the length of the struts increases along the stent; A method for operating a stent according to claim 13.

20. the plurality of bridges increase in length from a midline of the stent; A method for operating a stent according to claim 13.